Chronic Kidney Disease As A Modifier Of The Periodontitis-associated Microbiome And The Response To Periodontal Therapy by Araujo, Michel
University of Connecticut
OpenCommons@UConn
Master's Theses University of Connecticut Graduate School
6-21-2013
Chronic Kidney Disease As A Modifier Of The
Periodontitis-associated Microbiome And The
Response To Periodontal Therapy
Michel Araujo
UConn Health Center, michel.furtado@utoronto.ca
This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been
accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact
opencommons@uconn.edu.
Recommended Citation
Araujo, Michel, "Chronic Kidney Disease As A Modifier Of The Periodontitis-associated Microbiome And The Response To
Periodontal Therapy" (2013). Master's Theses. 452.
https://opencommons.uconn.edu/gs_theses/452
 I 
 
 
 
Chronic Kidney Disease As A Modifier Of The Periodontitis-associated 
Microbiome And The Response To Periodontal Therapy 
 
 
 
 
Michel V. Furtado Araújo 
B.D.S., Universidade Federal de Minas Gerais – Brazil, 2003 
M.Sc., University of Toronto – Canada, 2008 
 
 
 
A Thesis  
Submitted in Partial Fulfilment of the 
Requirements for the Degree of 
Master of Dental Science 
at the 
University of Connecticut 
2013  
 II 
 
 
APPROVAL PAGE 
 
 
Master of Dental Science Thesis 
Chronic Kidney Disease As A Modifier Of The Periodontitis-associated 
Microbiome And The Response To Periodontal Therapy 
 
 
Presented by 
Michel V. Furtado Araújo, B.D.S, M.Sc. 
 
 
Major Advisor________________________________________________ 
Dr. Patricia I. Diaz, D.D.S., M.D.Sc., Ph.D. 
Associate Advisor_____________________________________________ 
Dr. Efthimia Ioannidou, D.D.S., M.D.Sc. 
Associate Advisor_____________________________________________ 
Dr. Linda Strausbaugh, B.Sc., Ph.D. 
 
 
University of Connecticut 
2013 
 III 
ACKNOWLEDGEMENTS 
 
I am most grateful for the support provided by all professors at the Division of 
Periodontology at the University of Connecticut. The lively discussions during our seminars 
definitely made me a better clinician and researcher. To Dr. Schincaglia, my eternal gratitude for 
your limitless dedication and commitment to our education.  
 
 A very special thanks to all Periodontics residents. I extend my heartfelt gratitude to Sejal 
and Shiza, whose caring and friendship I try to pass forward everyday in the clinic. To Amy and 
Matt, I am thankful for getting to know you better this year. To Eric, Jonah, and Satoko for the 
time spent together and for letting me learn with you. To Phil for being the best co-resident one 
could ever wish for. Words cannot describe how enjoyable it was to be part of this group and 
how great were the laughs and tears we shared. You are all an extension of my (growing) family 
and I wish you all the very best in your future endeavors. 
 
Thanks to the students and staff of the Dr. Diaz lab. Mostly, I’d like to express my 
appreciation for Dr. Hong’s (Bo) help with the microbial data analyses. Without her hard work 
and patience this project would not be completed.   
 
I would also like to thank the members of my committee, Dr. Ioannidou and Dr. 
Strausbaugh, for their ideas, guidance, and continued support. I am most grateful to my major 
advisor, Dr. Diaz, for her mentorship, support, and commitment to excellence. Thank you for all 
the insightful recommendations, encouragement, and for believing in me. 
 
 I am eternally indebted to the love of my life, Michelle, who is the very best thing that 
has ever happened to me. To a little someone, who in about 7 months is going to drastically 
change my life for the better (much, much better). I will always love you. 
 IV 
 
APPROVAL PAGE         II 
ACKNOWLEDGEMENTS        III 
TABLE OF CONTENTS	  
1.	  Introduction ...................................................................................................................................... 1	  
1.1	  Chronic	  Periodontitis	  (CP) ....................................................................................................................1	  1.1.1	  Bacterial	  etiology	  of	  CP......................................................................................................................................1	  1.1.2	  Host	  response	  in	  CP.............................................................................................................................................5	  1.1.3	  Effects	  of	  non-­‐surgical	  periodontal	  therapy	  on	  the	  oral	  microbiome	  and	  clinical	  parameters	  of	  CP	  patients ...........................................................................................................................................7	  
1.2	  Periodontitis	  and	  Chronic	  Kidney	  Disease	  (CKD) .........................................................................9	  1.2.1	  CP	  prevalence	  in	  CKD	  patients ....................................................................................................................11	  1.2.2	  Microbiome	  of	  CKD	  patients.........................................................................................................................13	  1.2.3	  Effects	  of	  non-­‐surgical	  periodontal	  therapy	  on	  the	  oral	  microbiome	  and	  clinical	  parameters	  of	  CKD-­‐CP	  patients..............................................................................................................................14	  
1.3	  Rationale .................................................................................................................................................. 16	  
2.	  Objectives.........................................................................................................................................17	  
2.1	  Specific	  aims............................................................................................................................................ 17	  
2.2	  Hypotheses .............................................................................................................................................. 18	  
3.	  Study	  design	  and	  methods..........................................................................................................18	  
3.1	  Study	  populations ................................................................................................................................. 19	  
3.2	  Clinical	  study	  design............................................................................................................................. 20	  3.2.1	  Control	  patients	  with	  CP ................................................................................................................................20	  3.2.2	  CKD	  patients	  with	  CP.......................................................................................................................................21	  
3.3	  Clinical	  study	  procedures	  and	  sample	  collection....................................................................... 21	  3.3.1	  Visit	  0	  (Pre-­‐screening	  and	  nephrologist	  consultation	  for	  CKD	  patients	  with	  CP) ................21	  3.3.2	  Visit	  1	  (Screening	  and	  initial	  periodontal	  examination) ..................................................................22	  3.3.3	  Visits	  2	  (plaque	  collection;	  initial	  periodontal	  therapy)	  and	  3	  (completion	  of	  non-­‐surgical	  therapy) ............................................................................................................................................................................22	  3.3.4	  Visit	  4	  (Sample	  and	  clinical	  data	  collection	  after	  periodontal	  therapy)....................................23	  
3.4	  Microbiological	  laboratory	  procedures ........................................................................................ 23	  3.4.1	  DNA	  isolation ......................................................................................................................................................23	  3.4.2	  Microbiome	  determination	  using	  454	  pyrosequesencing...............................................................24	  3.4.3	  Processing	  and	  analysis	  of	  the	  bacterial	  sequences...........................................................................26	  
3.4.3.2	  Overall	  data	  analysis..................................................................................................................... 27	  
5.	  Results...............................................................................................................................................29	  
5.1	  Aim	  1.......................................................................................................................................................... 29	  
5.2	  Aim	  2.......................................................................................................................................................... 38	  5.2.1	  Baseline	  evaluation ..........................................................................................................................................38	  5.2.2	  Longitudinal	  evaluation	  –	  Control	  group................................................................................................44	  5.2.3	  Longitudinal	  evaluation	  –	  CKD	  group ......................................................................................................51	  
 V 
5.2.4	  Comparison	  of	  magnitude	  of	  clinical	  and	  microbiological	  changes	  pre-­‐	  to	  post-­‐Scaling	  and	  Root	  Planing	  (SRP)	  in	  CKDs	  and	  controls ..........................................................................................................57	  
6.	  Discussion ........................................................................................................................................61	  
6.1	  Periodontitis	  in	  CKD	  subjects	  is	  not	  associated	  with	  a	  unique	  subgingival	  microbiome	  
profile............................................................................................................................................................... 64	  
6.2	  Overall	  improved	  clinical	  characteristics	  result	  from	  SRP	  in	  Control	  and	  CKD	  subjects
............................................................................................................................................................................ 68	  
6.3	  Non-­surgical	  periodontal	  therapy	  does	  not	  drastically	  change	  the	  composition	  of	  
subgingival	  communities	  although	  it	  decreases	  the	  abundance	  and	  prevalence	  of	  certain	  
disease-­associated	  species........................................................................................................................ 71	  
6.4	  The	  microbiological	  response	  of	  Control	  and	  CKD	  subjects	  to	  non-­surgical	  periodontal	  
therapy	  follows	  opposite	  trends ............................................................................................................. 72	  
8.	  References .......................................................................................................................................75	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
1. Introduction  
1.1 Chronic Periodontitis (CP) 
1.1.1 Bacterial etiology of CP  
Chronic periodontitis (CP) is a bacterial-driven inflammatory disease that affects the tooth 
supporting connective tissues. This condition results from the interaction of specific bacterial 
communities with the immune response of susceptible individuals [1]. The composition and 
organization of dental biofilms are key factors that dictate the survival/proliferation of certain 
species at the expense of others and, in general, define periodontal health and disease states [2, 
3].  Specifically, while subgingival plaque samples from periodontally healthy patients comprise 
mainly aerobic Gram-positive rods or coccoid species, samples from CP patients depict a shift 
towards anaerobic Gram-negative rods and motile spirochetes [4-9]. In particular, Gram-positive 
rods such as Actinomyces naeslundii and Actinomyces viscosus are typical species found in 
healthy sites [4, 9, 10]. On the other hand, Aggregatibacter actinomycetemcomitans [1, 5, 7], 
Fusobacterium nucleatum [1, 6, 9, 10], Tannerella forsythia [1, 7, 11, 12], Campylobacter rectus 
[1, 5], Porphyromonas asaccharolytica [7], Prevotella melaninogenica [6, 8, 9], Porphyromonas 
gingivalis [1, 8, 10-12], Prevotella intermedia [1, 5, 8, 10], as well as the spirochete Treponema 
denticola [11, 12] have been all correlated with diseased sites. Furthermore, elevated counts of A. 
actinomycetemcomitans and P. intermedia have been found in sites with bleeding on probing 
(BoP) [5, 13], a clinical indicator of periodontal inflammation. Additionally, high proportions of 
F. nucleatum and Campylobacter rectus were more prevalent in active sites [5], whereas 
increased P. gingivalis [13, 14] counts have been found in deep pockets of CP patients. 
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For many years, bacterial culture was considered the gold standard assay to isolate and classify 
periodontal bacteria. This method is useful in establishing associations between diseases and 
certain microbes. In fact, as mentioned before, many known and un-named periodontopathogens 
were detected using selective and non-selective culture analyses from severe and chronic 
periodontitis patients. These studies allowed for the description of several taxa at species and 
sub-species levels [15, 16]. However, not all bacteria detected by the microscope can be grown 
in culture media. Moreover, culture-independent techniques have proven that microscopy and 
culture studies are incapable of clustering bacteria into similar phylogenetic groups [17-20]. 
Consequently, gene-derived methods were developed to overcome the limitations of culture 
studies. 
 
In particular, PCR amplification of the bacterial 16S rRNA gene, followed by cloning and 
sequencing has been used to describe oral bacteria [19-21]. This strategy revealed that 40% of 
the 327 species predicted to exist in the subgingival environment are uncultured [19]. An 
advantage of this technique is the fact that universal primers can be designed to quantify the total 
number of species of a sample [17, 19, 22]. Ribosomal RNA has been targeted due to its 
ubiquity, but preserved sequence variation; the former of which allows for accurate alignment, 
while the latter permits phylogenetic analysis [23, 24]. Specifically, the first two variable regions 
(V1 & V2) of the 16S rRNA gene result in improved power analysis in terms of number of 
phylotypes detected [25]. For microbial identification, the amplified sequences are then 
compared to database references [26, 27] at a suggested 97% sequence homology [28].  
 3 
Studies employing cloning and sequencing of the bacterial 16S rRNA gene allowed the 
identification of non-cultivable species in CP [19, 29, 30]. These molecular technologies 
demonstrated that known pathogens such as P. gingivalis, T. forsythia, and T. denticola comprise 
only a minor portion of the subgingival plaque [19]. Cloning revealed a novel Veillonella X042 
phylotype associated with periodontal health, while Filifactor alocis, a Gram-positive anaerobe, 
as well as some phylotypes of Selenomonas (CS015, CS002, FNA3) [18, 31], Treponema 
(VI:G:G47, Smibert-5) [31], and Pepstreptococcus [18] have been correlated with periodontal 
disease.  
 
More recently, a new sequencing technique, namely pyrosequencing, was developed, which 
obviates the need of plasmid cloning after PCR amplification. Pyrosequencing utilizes the 
detection of nucleotide incorporation during synthesis by pairing pyrophosphate release to a 
chemiluminescence signal [32]. Another advantage of pyrosequencing is its ability to generate a 
high number of sequences by emulsion PCR (emPCR), which can be sequenced simultaneously 
in a timely manner. This is particularly advantageous for the identification of phylotypes present 
in heterogeneous samples [33-36]. Different methods can be applied when pyrosequencing is 
used. Specifically, one bi-directional and two uni-directional sequencing methods were 
compared after 10 environmental samples were analyzed. Results showed that uni-directional 
sequencing produced increased reads (1.5-1.6 times higher than bi-directional sequencing) 
without compromising the outcome of microbial community analyses [37].  
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Pyrosequencing has been utilized in a few studies to evaluate the microbiome of CP patients [38, 
39]. Amplicons from the 16S rRNA hypervariable regions V1-V2 and V4 were sequenced from 
plaque samples of healthy and CP patients (shallow and deep pockets). The main disease-
associated phyla comprised Spirochaetes, Synergistetes, Bacteroidetes, and Firmicutes (Class 
Clostridia, Class Negativicutes, Class Erysipelotricha), while health-associated phyla were 
Proteobacteria and Firmicutes (Class Bacilli). The authors reported a significant difference in 
the community profiles when healthy sites were compared to shallow and deep pockets from CP 
patients. In particular, CP samples from deep pockets showed a tendency towards increased 
numbers of uncultivable species as well as elevated richness and evenness (Shannon index). 
Interestingly, P. gingivalis and T. denticola were associated with disease states as much as the 
Gram positive Filifactor alocis, while T. forsythia only ranked as the 16th most abundant disease-
associated organism [38]. Similarly, another study sequenced plaque samples aiming at assessing 
the relationship between inflammation (i.e presence of BoP) and the subgingival microbiome in 
CP, as well as evaluating differences in the microbiomes in health and disease Results showed 
that increased total microbial load and richness, as well as a shift in the subgingival communities 
were associated with periodontal destruction, but not with sites that bled upon probing. 
Periodontitis-prevalent operational taxonomic units (OTUs) included Treponema spp., 
Bacteroidetes spp., Synergistetes spp., Chloroflexi spp., OTUs from the TM7 phylum, and many 
OTUs from the Clostridia class (Firmicutes phylum). On the other hand, Actinomyces spp., 
Streptococcus spp., Proteobacteria, and certain Porphyromonas spp. were related to health [39]. 
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1.1.2 Host response in CP 
The shift from a healthy flora to a pathogenic one has dramatic implications on the immune 
system of the host. The inflammatory process seen in CP patients is characterized by the 
recruitment of an intense cellular infiltrate into the periodontal connective tissue. This infiltrate is 
mainly composed of plasma cells, B and T-cell lymphocytes, polymorphonuclear leukocytes 
(PMNs), monocytes, and macrophages (Figure 1) [40, 41]. As a consequence, an increased 
production and activation of host-derived enzymes, associated with an exacerbated inflammatory 
response, is followed by a gradual destruction of the tooth supporting connective tissues [42, 43].  
 
Figure 1. Proportions of cells in CP lesions. Plasma cells dominate, followed by B and T 
cells, while polymorphonuclear neutrophils (PMNs) and macrophages represent only a minor 
portion of immune cells. Other cells: fibroblasts, mast cells, and unidentified cells (adapted from 
[41]).  
 
Periodontopathogens have the ability to attach to cells/surfaces to invoke microbe-host 
interactions, invade and grow within host tissues, as well as evade or interfere with host defenses 
0%	  10%	  
20%	  30%	  
40%	  50%	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[42, 44]. Attachment to extracellular matrix, other microbial species, and host cells (i.e.: 
epithelial cells, gingival fibroblasts) is attained through surface appendages called fimbriae [45-
47]. This first interaction stimulates toll-like receptors 2 (TLR-2) and 4 (TLR-4) on epithelial 
cells, fibroblasts, and macrophages, which in turn induces the production of the pro-
inflammatory cytokines interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1ß), interleukin-6 (IL-
6), and tumor necrosis factor alpha (TNF-α) [48-52]. Some bacteria are also capable of invading 
epithelial cells, endothelial cells, and fibroblasts as a means to evade the host’s immune response 
[53-55]. This is the case of P. gingivalis, which uses fimbriae (FimA) and cysteine proteinases 
called gingipains to be internalized by epithelial cells and escape from the host’s defense [29, 
42]. Gingipains can also inhibit PMN bactericidal activity [56] and migration [57], inactivate 
complement C5a receptor of neutrophils [58, 59], and degrade immunoglobulins (Ig) IgG, IgA, 
and IgM [29, 60].  
 
Other bacterial virulence factors such as lipopolisaccharides (LPS), peptidoglycans (PGN), and 
lipoteichoic acid (LTA) stimulate the secretion of IL-1ß, TNF-α, IL-6, and IL-8 by epithelial 
cells. Diffusion of these and other cytokines into the gingival connective tissue causes direct or 
indirect stimulation of leukocytes, fibroblasts, mast cells, endothelial cells, dendritic cells, and 
lymphocytes [61-65]. Stimulated host cells release vasoactive molecules (TNF-α, prostaglandin 
E2 – PGE2, histamine), increasing the concentrations of exudative fluid proteins in the 
connective tissue and gingival crevicular fluid (GCF). In addition, leukocyte migration through 
the tissues is prompted by either bacterial (i.e.: formyl-methionyl-leucyl-phenylalanine - fMLP, 
fimbriae) or host chemoattractants (i.e.: monocyte chemotactic protein-1 - MCP-1, IL-8) [66-68]. 
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As an attempt to create space for the inflammatory infiltrate (exudate and leukocytes), fibroblasts 
activated by IL-1ß, TNF-α, and PGE2 secrete matrix metallo-proteinases (MMPs) that degrade 
collagen from the connective tissue compartment [69-71].  
 
CP can also elicit a systemic response since severe CP patients express elevated serum levels of 
inflammatory mediators. For instance, periodontally-derived cytokines (i.e.: IL-1ß, TNF-α, and 
IL-6) may reach the liver and activate hepatocytes to produce complement proteins and acute-
phase proteins such as lipopolysaccharide binding protein (LBP) and C-reactive protein (CRP), 
which facilitate bacterial phagocytosis by opsonization [63, 70].  
 
Overall, periodontal connective tissue and bone destruction result from the interaction of 
pathogenic bacterial communities with the host, leading to increased levels of inflammatory 
cytokines and tissue-destructive molecules (i.e.: MMPs, PGE2, and IL1-ß) against low levels of 
anti-inflammatory cytokines [72].  
1.1.3 Effects of non-surgical periodontal therapy on the oral microbiome and clinical 
parameters of CP patients 
Oral bacteria inhabit highly organized complex ecosystems called dental biofilms, which are also 
composed of bacterial products, proteins, an extracellular matrix of polysaccharides, and 
inorganic matter [73, 74]. Dental biofilms act as a distinct entity that provides an environment 
where bacteria can thrive while protected from the host defense and topical antimicrobial 
therapy. In this context, mechanical removal of irritants from teeth surfaces becomes paramount 
for successful periodontal treatment. Hence, scaling and root planing (SRP) represents the most 
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commonly employed form of periodontal therapy in both the initial and maintenance phases of 
treatment. This non-surgical therapy is designed to remove hard and soft deposits from tooth 
surfaces above and below the gingival margin [75-77]. 
 
The effect of SRP on the oral microbiota and clinical parameters of CP patients has been 
reported in many studies [78-80]. Beneficial outcomes include reduction in clinical inflammatory 
parameters/indices (i.e.: BoP, attachment loss - AL, plaque index - PI, gingival index - GI, 
pocket depth - PD) and pathogenic microbial counts from pre- to post-SRP.  
 
Culture analyses from periodontal pockets have shown an association between decreased counts 
of red complex members (i.e.: P. gingivalis, T. forsythia, and T. denticola) [81, 82] and 
decreased GI and PD after initial therapy [13, 82]. Also, most treated sites have been correlated 
with a decrease in the prevalence of P. gingivalis [13, 83], A. actinomycetemcomitans [83] and P. 
intermedia [83, 84] and an increase in A. viscosus [82]. Microscopy-based studies have shown 
that post-treatment proportions of spirochetes and total motile bacteria are reduced at the expense 
of the elevation on the prevalence of cocci [85]. 
 
A DNA-DNA checkerboard evaluation for 40 microbial species showed similar results to the 
microscopic/culture studies described above. Specifically, PD, BoP, AL, and plaque 
accumulation decreased significantly with increasing post-treatment levels of Actinomyces spp. 
and decreasing prevalence of T. forsythia and P. gingivalis. In addition, a strong association was 
found between decreases in both pocket depth and proportions of T. forsythia [86]. Clearly, one 
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of the more significant effects of SRP is to favor the prevalence and increased proportions of 
beneficial species, which might decrease the injurious effects derived from the presence of more 
pathogenic phylotypes, and decrease the abundance and prevalence of pathogenic species. No 
study, however, has evaluated the response to periodontal therapy using a global-scale 
microbiological approach. It is thus not clear if initial therapy radically changes the whole 
community towards one compatible with health. 
 
1.2 Periodontitis and Chronic Kidney Disease (CKD) 
Proper kidney function is crucial for homeostasis, blood filtration, and the production of essential 
hormones. Specifically, renal function regulates blood concentrations of ions, urea, glucose, and 
stimulates the production of hormones such as calcitriol, renin, and erythropoietin. As a result, 
electrolyte and blood pressure control, acid-base balance maintenance, and erythropoiesis are 
achieved [87]. In chronic kidney disease (CKD), renal function loss causes accumulation of 
water, waste, and toxic substances, which may result in conditions such as anemia, hypertension, 
acidosis, disorders of cholesterol and fatty acids, and bone disease. Once the extent of renal 
damage is past the point of compensation, patients develop end-stage renal disease (ESRD) and 
the treatments of choice are dialysis or kidney transplantation [88].  
 
CKD has been classified in five stages, with stage 1 being the mildest and usually causing few 
symptoms and stage 5 being a severe illness with poor life expectancy if untreated (Table 1). 
Based on the National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
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Guidelines, patients with CKD stage 5 are treated with hemodialysis (HD) when the weekly 
renal urea clearance falls below 2.0, which is a sign of uremia [89].  
 
Table 1. Stages of Chronic Kidney Disease  
Stage Description 
Glomerular filtration 
rate (mL/min/1.73m2) 
1 Slight kidney damage with normal or increased filtration More than 90 
2 Mild decrease in kidney function 60-89 
3 Moderate decrease in kidney function 30-59 
4 Severe decrease in kidney function 15-29 
5 Kidney failure  Less than 15 (or dialysis) 
 
One of the major aspects of CKD is an immune depletion state, which can be caused by 
underlying conditions that led to renal failure (i.e. diabetes mellitus, vascular disease), uremia or 
therapy (i.e. dialysis and transplantation) [90]. Such immuno-incompetence may derive from 
defective antigen recognition [91] and antibody formation [92], as well as impaired neutrophil 
function [93-96]. Therefore, mainly two cell types are involved in the immunodeficiency seen in 
CKD: lymphocytes and phagocytes. Specifically, serum accumulation of toxins has been shown 
to alter the activation of monocytes, B- and T-cells [91, 97-99], and neutrophils [93-96].  
 
The accumulation of toxic substances in the uremic plasma has been reported to promote 
abnormal superoxide production [93-96], decreased neutrophil chemotaxis [93, 96, 100], 
phagocytosis [94, 95, 101], and intracellular killing [93, 95]. As a result, these patients present an 
increased susceptibility to infections [91, 92, 97], having elevated mortality rates from sepsis 
[90, 102]. 
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On the other hand, the production of cytokines that activate B- and T-cells (IL-2 and INF-γ) is 
reduced in CKD patients [103-105]. However, it has been shown that there is no intrinsic defect 
on T-cells. Rather, an insufficient co-stimulatory effect of the antigen presenting cells (APCs; i.e. 
monocytes) was found to play a role in the impaired activity of lymphocytes [99, 106]. For 
instance, T-helper cells (or CD4+ cells) recognize and amplify the signals from APCs and can 
develop into either Th1 or Th2. Th1 cells produce interferon-gamma (INF-γ) and promote 
cellular effector function, while Th2 cells are accessory to B-cells for immunoglobulin 
production [107]. Both Th1 and Th2 are present in low numbers in dialysis patients, but CKD 
patients show an increased tendency for Th1 differentiation. Such bias towards Th1 development 
is due to increased levels of IL-12 produced by APCs/monocytes [105], which results in even 
less B-cell activity. In addition, uremia and HD interfere with monocyte function because of 
repeated complement activation. In this millieu, monocytes are required to produce high levels of 
the pro-inflammatory cytokines IL-1 and IL-6. However, this chronic activation leads to immune 
failure when no active infection is present since high levels of pro-inflammatory cytokines result 
in low T-cell activation [90]. 
 
All in all, the proneness of infection seen in CKD patients is a result of hampered cellular and 
humoral mechanisms. Monocytes, macrophages, B- and T-cells are affected, which render the 
host ineffective in producing adequate responses to bacterial/inflammatory insults [97, 108].  
1.2.1 CP prevalence in CKD patients 
Both CKD and CP are characterized as inflammatory diseases that compromise the host’s 
immunologic response and have drastic systemic implications [109-112]. In this context, 
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associations have been made in the literature, which speculate a predisposition of CKD patients 
to periodontal disease. However, evidence on the prevalence of periodontitis in the CKD 
population has been conflicting. While some studies showed no difference in the prevalence of 
periodontitis between the general and the CKD population [113-115], others showed a higher 
prevalence of CP in the CKD patients [116-119]. These controversial results may be due to 
discrepancies in study designs (i.e. lack of controls, CP and CKD definition) and bias (i.e. failure 
to account for confounding factors). 
 
Recent evidence, nevertheless, gives credence to a strong correlation between CP and CKD [119, 
120]. For instance, in a study that examined the prevalence of CP in CKD patients, it was found 
that CKD patients had significantly more CP when compared to non-CKD controls (14.7% 
versus 8.7%). Furthermore, Mexican-Americans and non-Hispanic Blacks with CKD showed 
increased odds ratios for CP (OR 1.70 and 1.30, respectively) after statistically adjusted for age, 
sex, smoking, diabetic status, control and duration, as well as for body mass index (BMI), 
cardiovascular disease, and hypertension [119]. Another study used multivariate logistic 
regression models to control for 14 potential CKD risk factors and showed diabetes duration and 
hypertension as indirect mediators between CP and CKD. These results were further tested by 
structural equation models, which not only corroborated diabetes duration and hypertension as 
mediators of the effect of CP on CKD, but also demonstrated a bidirectional relationship 
between CP and CKD [120]. 
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1.2.2 Microbiome of CKD patients 
As stated above, the inter-relationship CP-CKD may derive from the increased proneness of 
CKD patients to microbial infection and its related inflammatory challenge. Therefore, it seems 
reasonable to expect that CKD patients would present increased levels/proportions of 
periodontopathogenic bacteria. 
 
A recent study evaluated the severity of CP in patients with and without CKD by examining 
clinical parameters (PD and AL) and plaque samples by polymerase chain reaction (PCR) 
analysis using 16S/18S rRNA primers for Candida albicans, F. nucleatum, A. 
actinomycetemcomitans, Prevotella nigrescens, P. intermedia, Eikenella corrodens, P. 
gingivalis, T. denticola, and T. forsythia. Results showed that CP was more severe in CKD 
patients compared to non-CKD patients. Also, an association was found between clinical 
attachment levels and the prevalence of C. albicans, P. gingivalis, and T. denticola in CKD 
patients with CP. Statistically significant higher frequencies of C. albicans, P. gingivalis, T. 
forsythia, and T. denticola were found for CKD compared to non-CKD subjects. This work, 
however, failed to control for important confounding factors such as diabetes and hypertension 
[121]. 
 
Interestingly, a PCR evaluation of plaque from hemodialysis patients reported increased levels of 
P. gingivalis, T. forsythia, and P. intermedia compared to age and sex-matched controls. 
However, increased levels of periodontopathogenic bacteria were not correlated with attachment 
loss and end-stage renal disease (ESRD) was not associated with more severe periodontal 
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destruction [114]. Similarly, increased BANA test scores for red complex bacteria were found in 
shallow to moderate pockets (3-5mm) of CKD patients, while equivalent scores were seen in 
deep pockets (>5mm) of matched controls with periodontitis. However, despite having increased 
plaque and calculus accumulation indices, CKD patients showed decreased PD compared to 
Control patients with periodontitis [122].  
 
These limited studies suggest that CKD may predispose the host to harbor increased levels of 
periodontal pathogens. Impaired immune responses, however, may be responsible for a lack of 
correlation between these increased levels and periodontitis severity. 
1.2.3 Effects of non-surgical periodontal therapy on the oral microbiome and clinical 
parameters of CKD-CP patients  
The reported increased levels of periodontopathogens allied with the elevated CP prevalence in 
CKD patients underscore the importance of periodontal treatment to control infection in these 
patients. Periodontal treatment success should be measured not only by improvements in clinical 
parameters (i.e. PD, GI, PI, AL), but also by analysis of microbiological outcomes. 
 
The importance of effective periodontal treatment in CKD patients is further highlighted by the 
fact that CP may contribute to the chronic inflammation present in CKD [123], as well as to 
other inflammatory conditions such as cardiovascular diseases (CVD) [124-127] and diabetes 
mellitus (DM) [128-131]. This is believed to be due to the systemic diffusion of pathogenic 
bacteria and their products. For instance, P. gingivalis, A. actinomycetencomitans, P. intermedia, 
T. denticola, and E. corrodens have been found in atherosclerotic plaques [54, 132]. Bacterial 
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contact with and invasion of the endothelium induce the expression of intercellular adhesion 
molecule (ICAM), vascular cell adhesion molecule (VCAM), IL-8, IL-6, MCP-1, and TLR-4 
[52, 133, 134].  
 
Although many studies evaluated the effect of SRP in subjects with other chronic inflammatory 
conditions, only two studies were found which examined the outcomes of SRP in CKD patients 
[113, 135]. In Artese et al. [113], the response of 21 pre-dialysis subjects with CP to SRP was 
compared to that of 19 systemically healthy patients with CP matched for gender, BMI, 
ethnicity, and smoking status. Non-CKD patients with CP responded similarly to CP-CKD 
patients. Specifically, a significant decrease in gingival bleeding, visual plaque, suppuration, 
BoP, PD, and AL with no difference between the groups was seen at 3 months post-SRP. In 
addition, statistically increased GFR (as assessed by the Cockcroft and Gault equation) was 
found for both groups [113]. However, CKD subjects in this study were in the pre-dialysis stage 
and perhaps were yet to develop the severe uremic state seen in dialysis patients, which may 
compromise immune responses and wound healing. Furthermore, this study did not include a 
comparative assessment of the microbiomes of the two populations.  
 
Another study from the same authors is the only work that analyzed the clinical and 
microbiological outcomes of SRP in CKD-CP and CP patients [135]. At 3 months post-SRP both 
groups showed significant clinical improvements as assessed by PD, CAL, and visual plaque. 
DNA-DNA hybridization was performed to evaluate the presence and levels of 49 species. At 
baseline, the periodontitis-associated subgingival microbiota of CKD and CP had similar 
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composition. Enterococcus faecalis was the only species detected in higher counts in CP patients 
compared to CKD-CP. At 3 months post-SRP, there was a significantly decreased level of most 
species on the CP group, but only Actinomyces gerencseriae, Actinomyces oris, A. 
actinomycetemcomitans, Fusobacterium nucleatum ssp. polymorphum, Streptococcus 
constellatus, Leptotrichia buccalis, Dialister pneumosintes, enterics, and Staphylococcus aureus 
decreased in the CKD-CP group. Moreover, Prevotella nigrescens increased post-therapy in the 
CKD-CP group. CKD-CP patients also presented increased post-SRP levels of Actinomyces 
israelii, C. rectus, Fusobacterium periodonticum, Parvimonas micra, Prevotella nigrescens, T. 
forsythia, Neisseria mucosa, and Streptococcus anginosus when compared to the CP control 
group post-therapy Furthermore, sites that lost attachment after SRP in CKD-CP patients showed 
increased levels of T. forsythia, P. gingivalis, T. denticola, and Fusobacterium spp. when 
compared to sites that responded well to initial periodontal therapy. Overall, the authors found 
persistent high levels of many pathogenic bacteria in CKD-CP patients and hypothesized a 
correlation between uremia and the immunocompromised state of these patients with a rapid re-
colonization by pathogenic species after non-surgical periodontal therapy. No study, however, 
has used pyrosequencing of 16S rRNA amplicons or another global approach to compare the 
response to SRP in CKD patients. 
1.3 Rationale  
In summary, periodontal disease is an inflammatory-infectious condition caused by changes in 
the subgingival microbiome that culminate in destruction of the tooth-supporting tissues. This 
disease has been shown to contribute to an elevated systemic burden by the release of pro-
inflammatory cytokines, which in turn may exacerbate the inflammatory state of CKD patients. 
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Hence, efficacious treatment of CP is of utmost important in this population. However, the 
uremic state of CKD subjects may predispose them to increased periodontal destruction, either 
by modifying the infection burden or the inflammatory responses. Compromised immune 
responses and wound healing in CKD patients could also compromise the response to 
periodontal therapy. The literature investigating possible differences in the infection burden in 
the subgingival environment in CKD patients is scarce with available studies indicating either 
some differences in carriage of periodontopathogens or no difference. No study however, has 
evaluated potential differences in the subgingival microbiome between CKD and control patients 
using a global-scale approach. Similarly, only a few studies, with controversial outcomes, have 
evaluated the clinical response of CKD patients to periodontal therapy and no study has 
evaluated microbiological outcomes at a global scale. Therefore, in this study we will compare 
the clinical and microbiological profiles of CKD patients and controls with chronic periodontitis 
at baseline and after initial therapy, evaluating the subgingival microbiome via high throughput 
sequencing. This study will allow us to better understand the interaction between host and 
bacterial insult in CKD, potentially deconvoluting the mechanisms through which CKD and CP 
correlate.  
 
2. Objectives 
2.1 Specific aims 
 Aim 1. To compare the subgingival microbiome composition of non-CKD (Control) and 
CKD subjects with CP.   
 Aim 2. To evaluate and compare the clinical and microbiological response to non-
surgical periodontal treatment in non-CKD (Control) and CKD subjects with CP.  
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2.2 Hypotheses 
The presence of CKD alters the colonization patterns of oral microorganisms during CP and 
affects the response and microbiological outcomes after periodontal therapy. Therefore, our 
hypotheses are that:  
Different microbiomes are associated with CP in CKD compared to Control patients. 
 
Control and CKD patients with CP will show similar improvements in periodontal clinical 
parameters, but pathogen microbiota reduction from pre- to post-SRP will be limited for CKD 
patients with CP compared to Control patients with CP.  
 
Null Hypothesis 1: There is no difference between the microbial profiles of CKD and Control 
patients with CP. 
Null Hypothesis 2: There is no difference in the clinical and microbiological response to non-
surgical periodontal therapy for Control and CKD patients with CP.  
3. Study design and methods 
To achieve the above-described objectives, plaque samples were collected before and after non-
surgical treatment for CP. The microbiome composition of these samples was then determined 
by high-throughput 454 pyrosequencing of the bacterial 16S rRNA gene. Clinical baseline 
parameters and their change in response to periodontal treatment were also evaluated. 
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3.1 Study populations 
Two subject cohorts were included in this study. The first group comprised patients with CKD 
and CP, who were recruited from the University of Connecticut Dialysis Center (UCDC), the 
Springfield Dialysis Center in Springfield, Massachusetts, and other dialysis centers in the 
surrounding area including Dialysis Units in Newington, Forestville, Southington, Agawam and 
Chicopee. The second group included Control patients with CP, who were referred for 
periodontal treatment to the Periodontology Graduate Clinic at the University of Connecticut 
Health Center (UCHC). Table 2 shows the inclusion and exclusion criteria for the cohorts of this 
study, while Table 3 shows a specific exclusion criterion for CKD patients with CP and 
exclusion criteria for Control patients with CP. 
Table 2. Inclusion/exclusion criteria for CKD and Control patients with CP. 
Inclusion criteria Exclusion criteria 
• At least one site with probing depth (PD) of 5mm 
or more and two or more interproximal sites with 
clinical attachment loss (CAL) equal or more than 
6mm [136]; 
• A minimum of 15 teeth; 
• No history of antibiotic use within the last month, 
and 
• No history of periodontal treatment within the last 
year. 
• Inability or unwillingness to follow the study 
protocol; 
• Severe co-morbid conditions likely to affect life 
expectancy within 1 year (for example, metastatic 
cancer), and 
• Dementia, pregnancy or lactation, and smoking. 
 
 
Table 3. Specific exclusion criteria for Control and CKD groups. 
Exclusion criterion for CKD patients with CP Exclusion criteria for Control patients with CP 
• History of vascular access infection or clotted 
access within the last month. 
• Systemic diseases that are not controlled (i.e diabetic 
or hypertensive patients with cardiovascular disease 
not taking medications to control their condition), 
and 
• Immunocompromising conditions such as HIV, 
rheumatoid arthritis, CKD or history of 
chemotherapy or radiotherapy (in the previous five 
years). 
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3.2 Clinical study design 
3.2.1 Control patients with CP 
Control patients with CP were recruited from subjects undergoing initial phase of periodontal 
treatment in the Periodontology Graduate Clinic at UCHC. Subjects were seen for at least four 
visits. The first visit included patient screening and orientation, followed by informed consent 
signature. Medical history and periodontal clinical parameters were also collected. The second 
visit occurred at the time of initial periodontal treatment (SRP), at which time plaque samples 
were collected. At the third visit, initial periodontal treatment was completed. Finally, the fourth 
visit was booked at the re-evaluation exam (2 months after SRP), when retrieval of plaque 
samples and documentation of the final clinical parameters were conducted (Figure 2). 
 
Figure 2. Schematic representation of study design and visit procedures. Visit 1 included analysis of 
medical history and periodontal examination. Plaque collection as well as scaling and root planing 
were performed in visit 2. Visit 3 encompassed completion of non-surgical periodontal therapy. Visit 
4 consisted of plaque collection and periodontal examination. 
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3.2.2 CKD patients with CP 
CKD patients with CP were recruited from the various dialysis centers as previously described. 
This group was subjected to one pre-screening visit prior to the visits described for Control 
patients with CP. This visit (visit 0) included an analysis of whether subjects fit into the inclusion 
and exclusion criteria by their primary provider (nephrologist) to determine initial eligibility for 
the study (Figure 3). 
 
 
3.3 Clinical study procedures and sample collection 
3.3.1 Visit 0 (Pre-screening and nephrologist consultation for CKD patients with CP) 
Before starting their periodontal treatment, CKD patients with CP were subjected to a pre-
screening and a consultation with their primary provider (nephrologist). At this stage, the 
nephrologist determined initial eligibility for the study based on criteria 3 (no history of 
Figure 3. Schematic representation of study design and visit procedures. Visit 0 included pre-
screening of CKD patients by their nephrologists. Visit 1 included analysis of medical history and 
periodontal examination. Plaque collection as well as scaling and root planing was performed in visit 
2. Visit 3 encompassed completion of non-surgical periodontal therapy. Visit 4 consisted of plaque 
collection and periodontal examination. 
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antibiotic use within the last month) and 5 (no history of vascular access infection or clotted 
access within the last month). 
3.3.2 Visit 1 (Screening and initial periodontal examination) 
Procedures of this appointment included review of medical history and a full mouth periodontal 
examination, which was performed at six sites per tooth as follows: 
• Plaque score (PS): presence or absence of plaque was measured with the use of disclosing 
solution. Scores were stratified as 0: no plaque; 1: presence of plaque. Percentage of sites with 
plaque was then calculated for each subject [137]; 
• Pocket probing depths (PD): distance in millimeters from the gingival margin to the base 
of the pocket upon gentle probing with a Michigan probe; 
• Bleeding on probing (BoP): presence or absence of bleeding after gentle probing. 
Percentage of bleeding sites was then calculated for each subject, and 
• Clinical attachment levels (CAL): distance in millimeters from the cemento-enamel 
junction to the base of the pocket using a Michigan probe. 
 
3.3.3 Visits 2 (plaque collection; initial periodontal therapy) and 3 (completion of non-
surgical therapy) 
Plaque samples were collected at the time patients presented for initiation of periodontal therapy 
(SRP). Subjects were asked not to eat or drink for 1 hour prior to the study visit. Plaque was 
collected from the deepest pocket in two different quadrants and the two samples pooled. 
Collection procedures involved removal of supragingival plaque with a curette and sampling of 
subgingival plaque with individual sterile Gracey curettes. Plaque samples were immediately 
placed in a polypropylene tube containing 50µl Tris-EDTA (TE) buffer and stored at -80ºC. 
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After plaque collection, patients received initial periodontal therapy, which involved SRP 
performed according to regular standard of care. Some patients required 2 visits to complete 
initial periodontal treatment (visits 2 & 3). 
3.3.4 Visit 4 (Sample and clinical data collection after periodontal therapy) 
Visit 4 was booked at 2 months after completion of initial periodontal treatment. Plaque samples 
were collected and stored at the beginning of the visit in the same manner as described in visit 2. 
Next, a full mouth periodontal examination was performed and recorded using the same 
approach described for visit 1. 
3.4 Microbiological laboratory procedures 
For microbiological analysis, DNA was isolated from plaque samples resuspended in buffer. 
DNA was used as a template for triplicate PCR reactions with universal primers for the V1 and 
V2 regions of 16S rRNA gene. Microbial amplicon libraries were then sequenced with titanium 
454 pyrosequencing chemistry (Figure 4).  
 
 
 
 
 
 
3.4.1 DNA isolation 
Subgingival plaque samples were collected and placed in 50µl of Tris-EDTA (TE) buffer. 
Samples were re-suspended in lysis buffer with lysozyme at 37°C for 30 minutes. Next, 
Figure 4. Sampling strategy: plaque samples were used for isolation of bacterial DNA, which 
was used for amplicon library preparation and sequencing by titanium 454 pyrosequencing. 
Plaque DNA isolation 
Microbiome 
determination  
(454 pyrosequencing) 
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proteinase K and AL buffer (Qiagen DNA extraction kit) were added and incubated at 56°C 
overnight. Inactivation of proteinase K was performed by heating the suspension at 95°C for 5 
minutes. DNA isolation was performed using the Qiagen DNeasy Blood and Tissue kit (Qiagen, 
Valencia, CA) by following the manufacturer’s instructions. The final solution was eluted in 
50µl of MD5 solution (MoBio) and DNA concentration was measured using a Nanodrop 
instrument (ND-1000; light spectrophotometry at 260nm). Positive controls (180µl of a known 
bacterial culture) and negative control samples for the assessment of sample contamination by 
foreign DNA (180µl of lysis and TE buffers without any sample) were also included. 
3.4.2 Microbiome determination using 454 pyrosequesencing 
Amplicon libraries were prepared using fusion primers with adaptor primers “A” and “B” (Table 
4), universal primers (Table 5), and 13 different multiplex identifier tags (MIDs – Table 6). A 
schematic representation of the fusion primers is shown in Figure 5. These primers amplify a 425 
bp fragment covering the regions V1 and V2 of the 16S rRNA gene.  
 
PCR was performed in thin-walled tubes with a C1000 Touch Thermocycler (BioRad, Hercules, 
CA). Each reaction was performed in triplicate using a total volume of 25µl containing 5µl of 
DNA template, 2.5µl of 10X PCR buffer, 0.75µl of MgCl2, 0.5µl of deoxynucleoside 
triphosphates (dNTPs 10mM), 0.125µl of Taq polymerase, 15.625µl of PCR water and 0.25µl of 
each primer. PCR conditions were as follows: pre-heating of samples at 95°C for 3 minutes, 
denaturation at 95°C for 30 seconds, annealing at 50°C for 30 seconds, and elongation at 72°C 
for 60 seconds. In total, 25 cycles were conducted, which were followed by a final elongation 
step at 72°C for 9 minutes. Reaction products were evaluated by gel electrophoresis (1.5% 
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agarose gel run at 100V for 20 minutes), DNA was stained using ethidium bromide and 
visualized under short-wavelength UV-light (Gel-Doc system, BioRad). The Qiagen PCR kit 
was used to purify PCR products. Finally, amplicon library quantification was also conducted 
using Experion DNA chip (BioRad, Hercules, CA) and bacterial amplicon libraries sequenced 
with titanium 454 pyrosequencing chemistry. 
 
Tables 4, 5 & 6. List of fusion primers used for pyrosequencing.  Adaptor sequences are shown 
in table 4, universal primers are displayed in table 5, and MIDs are listed in table 6.  
 
 
 
 
 
 
 
 
 
 
Table 4 
Adaptor sequences A and B 
5’-CCATCTCATCCCTGCGTGTCTCCGACTGAG-3’ 
5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3’ 
 
Table 5 
Universal primers 
Forward 5’-AGAGTTTGATCMTGGCTGAC-3’ 
Reverse 5’-CYIACTGCTGCCTCCCGTAG-3’ 
 
Table 6 
MIDs 
ACGAGTGCGT 
ACGCTCGACA 
AGACGCACTC 
AGCACTGTAG 
ATCAGACACG 
ATATCGCGAG 
CGTGTCTCTA 
CTCGCGTGTC 
TAGTATCAGC 
TCTCTATGCG 
TGATACGTCT 
CATAGTAGTG 
CGAGAGATAC 
 
Figure 5. Fusion primers design. Adaptor sequences A and B, MID, forward and reverse primers, and 
bacterial DNA template. 16S RNA variable regions V1 and V2 were amplified. Adaptor sequence A or 
B bind to emPCR beads while unidirectional sequencing starts from the opposite end. MIDs serve to 
tag each sample, allowing for massive parallel sequencing.  
 
Adaptor A MID Forward primer 
V1   V2  
V1   V2  
Reverse primer MID Adaptor B 
Locus specific  
PCR amplification (425bp) 
V1   V2  
V1   V2  
Adaptor A MID Forward primer 
Adaptor A MID Forward primer 
Reverse primer MID Adaptor B 
Reverse primer MID Adaptor B 
 26 
Emulsion PCR (emPCR) and unidirectional sequencing were performed according to the 
Sequencing methods manuals (Roche Life Sciences) at the Center for Applied Genetics and 
Technology of the University of Connecticut (Storrs-CT). Briefly, libraries were diluted and 
amplified using a Roche 454 GS titanium Small Volume emPCR kit (Lib-L) at a ratio of two 
molecules of library per bead. Enriched beads were loaded in ten regions of two eight-region GS 
titanium PicoTiter plates and sequenced with a GS titanium sequencing kit (XLR70) for 200 
cycles on a Roche 454 GS FLX pyrosequencer. Raw image data were processed on a computer 
cluster with Roche 454 data analysis processing software.  
3.4.3 Processing and analysis of the bacterial sequences 
3.4.3.1 Sequence pre-processing 
Sequences were processed using the Mothur software [138]. Primers were removed and samples 
were separated according to their MID. Sequence quality was then assessed using Pyronoise 
[139] as implemented in Mothur. Next, alignment and sequence distance calculation were 
conducted, and sequences clustered into operational taxonomic units (OTUs) based on a 3% 
discrepancy [28]. Classification of sequences was performed using the Ribosome Database 
Project (RDP) classifier [26] and the Human Oral Microbiome Database (HOMD) 
(www.homd.org) and the RDP trainset as templates. OTUs were classified according to the 
majority taxonomic assignments.  
 
HOMD was used as a primary reference at the species level. When species nomenclature was not 
specified by HOMD, a consensus between RDP and HOMD was sought at the genus level. 
When such consensus was not reached, RDP was used as the primary reference. The terminology 
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“Unclassified” plus the nearest taxonomic level at which classification was possible was 
employed thereafter. For OTUs not classified at a species level, the representative (middle) 
sequence of each OTU was compared via BLAST against the HOMD. This BLAST 
classification was reported if results showed more than 97% similarity to a HOMD oral taxon. In 
such case, the oral taxon (OT) name was reported in parentheses as part of the OTU taxonomy. 
3.4.3.2 Overall data analysis 
A schematic representation of the analyses conducted in this work is displayed in Figure 6. 
Clinical and microbiological assessments were performed in CKD and Control patients with CP 
in cross-sectional (Aim1) and longitudinal (Aim2) fashions. Clinical and non-dichotomous 
demographic data were expressed as means ± standard deviation, median, and range. 
Demographic dichotomous data (i.e.: gender, ethnicity, diabetes status) were presented as 
percentage of subjects. Microbial data were expressed as mean percentage ± standard deviation 
or percentage prevalence. Statistical significance was considered when p values were <0.05 after 
adjusment for multiple comparisons, if appropriate. 
Microbiome analysis 
Microbiome analysis included evaluation of alpha (α-) and beta (ß-) diversity (Figure 6). OTU 
prevalence was assessed by employing the appropriate statistical methods (chi-square (χ2) and 
McNemar for categorical unrelated and related data, respectively); OTU abundance was 
evaluated by the LEfSe algorithm [140] or via Wilcoxon Signed Rank test for non-parametric 
unrelated and related data, respectively. 
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Alpha diversity analysis comprised samples richness, evenness, and total diversity. Richness was 
assessed by the evaluation of the number of observed OTUs. Evenness was obtained using the 
Shannon evenness index, while total diversity was evaluated by the Simpson and the Shannon 
indices [141-143]. Appropriate statistics for parametric and non-parametric data were employed 
to assess differences in α-diversity (Aim 1: independent t-test or Mann Whitney; Aim 2: Paired 
t-test or Wilcoxon Signed Ranks). 
 
Beta diversity analysis was performed by calculating the distance between communities using 
principal coordinate analysis (PCA) based on ThetaYC [144] and Jaccard similarity indices 
[145], as well as Unifrac metrics [141]. 
Demographic and Clinical Data Analyses 
Demographic, clinical, and microbial parameters were evaluated using Statistical Product and 
Service Solutions software (SPSS – Chicago, IL).  
 
For cross-sectional comparisons (Aim 1) independent sample tests were used, while appropriate 
paired tests were used for longitudinal analyses, according to the nature of the data (continuous or 
nominal) and its distribution. A comparison between the groups was also performed to evaluate 
the changes (delta) in clinical and microbiological results. Pre-SRP values were subtracted from 
post-SRP values and the outcomes were contrasted between CKD and Control subjects. 
Therefore, negative values for the clinical parameters evaluated imply improvement from pre-
SRP to post-SRP.  
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5. Results 
5.1 Aim 1 
The first aim of this thesis (Aim 1) was to compare the subgingival microbiome composition of 
Control and CKD subjects with CP. Initially, we were able to enroll 17 control subjects and 15 
CKD subjects. The two groups, however, were not matched in terms of demographic, medical 
(diabetes) and clinical periodontal characteristics. Therefore, only 13 controls and 14 CKDs were 
selected for the final analysis to achieve matching of the groups by age (p=0.55), gender 
(p=0.52), ethnicity (white and non-white – hispanic and african-americans; p=0.56), and diabetes 
status (p=0.06) (Table 7). Similarly, mean PD (p=0.07), mean CAL (p=0.33), BoP% (p=0.13), 
and PS% (p=0.10) were comparable between Control and CKD patients. The only difference 
between the two groups was in the percentage of sites with PD≥5mm (p=0.049), an indication of 
disease extent, which was marginally increased in Control patients.  
 
 
CKD subjects with 
CP 
Before SRP 
After SRP 
Control subjects 
with CP 
 
Before SRP 
After SRP 
AIM2 
 Clinical & demographic analyses 
α-diversity 
ß-diversity 
Taxa relative abundance 
Taxa Prevalence 
AIM1 
 Clinical & demographic analyses 
α-diversity 
ß-diversity 
Taxa relative abundance 
Taxa Prevalence AIM2 
 Clinical & demographic analyses 
α-diversity 
ß-diversity 
Taxa relative abundance 
Taxa Prevalence 
AIM2 
 Clinical & demographic analyses 
α-diversity 
ß-diversity 
Taxa relative abundance 
Taxa Prevalence 
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Table 7. Clinical and demographic analyses of Control and CKD patients with CP. Control 
subjects presented marginally increased percentage of sites with PD≥5mm (PD: pocket depth; 
CAL: clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm: millimeters; data are 
presented as percentage of individuals or mean ± standard deviation, median, and range). 
Characteristic Control (13) CKD (14) Statistical test (p value) 
Age 
(Years) 
48.4±10.6 
(48; 32-69) 
60.1±16.1 
(61; 22-80) 
t-test (p=0.55) 
Gender 
(M: male; F: female) 
M = 69.2% 
F = 30.8% 
M = 57.1% 
F = 42.9% 
Chi-square (p=0.52) 
Ethinicity 
(W: white; NW: non-white) 
W = 38.5% 
NW = 61.5% 
W = 57.1% 
NW = 42.9% 
Chi-square (p=0.56) 
Diabetes status 
(Y: yes; N: no) 
Y = 15.4% 
N = 84.6% 
Y = 50.0% 
N = 50.0% 
Chi-square (p=0.06) 
Mean PD (mm) 3.3±0.64 
(3.15; 2.4-5.0) 
3.0±0.54 
(2.84; 2.4-4.3) 
Mann Whitney (p=0.07) 
Mean CAL (mm) 3.6±0.9 
(3.40; 2.4-6.0) 
3.7±1.38 
(3.13; 2.5-7.5) 
Mann Whitney (p=0.33) 
BoP 
(% of sites) 
52.0±25.0 
(49; 16-100) 
37.0±25.0 
(32; 1-89) 
t-test (p=0.13) 
PS 
(% of sites) 
59.0±20.0 
(62; 30-100) 
74.0±25.0 
(82; 29-100) 
t-test (p=0.10) 
PD ≥ 5mm 
(% of sites) 
21.0±15.0 
(18; 4-65) 
13.0±12.0 
(8; 3-45) 
Mann Whitney (p=0.049) 
 
Stratification of PD into 1-3mm, 4-5mm, and >5mm also depicted a marginally significant 
difference in the percentage of sites with PD>5mm for the Control group (Figure 7; p=0.049). In 
contrast, similar CAL distributions were seen between Control and CKD cohorts (Figure 8) 
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Figure 7. Stratified pocked depth distribution. An increased percentage of sites with PD>5mm 
was found in Control individuals (Mann Whitney = 1-3mm: 0.2; 4-5mm: 0.13; >5mm: 0.015). 
 
 
 
Figure 8. Stratified clinical attachment levels distribution. No differences were found between 
Control and CKD subjects (Mann Whitney = 1-3mm: 0.73; 4-5mm: 0.06; >5mm: 0.18). 
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Clinical analyses of sites sampled for microbiological evaluation are shown in Figure 9. There 
was a trend for higher PDs in sampled sites of Controls. This difference, however, was not 
statistically significant. 
 
 
 
 
 
 
Figure 9. Similar PD and CAL were found in sampled sites of Control and CKD subjects 
(Independent t-test = PD: 0.06; CAL: 0.74). 
 
Subgingival plaque analysis from 13 Control and 14 CKD patients with CP rendered 874 
species-level operational taxonomic units (OTUs). A comparison of CKD and Control 
communities revealed no statistical differences in α-diversity (Table 8). 
Table 8. α-diversity analysis depicted comparable subgingival plaque communities in Control 
and CKD patients (data presented as mean ± standard deviation).  
 
 Control (13) CKD (14) Ind t-test (p value) 
Number of observed OTUs 175.3±45.4 147.1±56.0 p=0.16 
Estimated OTUs 301.5±120.6 236.4±97.8  p=0.14 
Inverse Simpson 14.9±8.1 14.6±11.0 p=0.95 
NP Shannon 3.4±0.6 3.2±1.0 p=0.43 
Shannon evenness 0.65±0.1 0.6±0.2 p=0.60 
 
Principal component analysis (PCA) of distance among samples based on ecology metrics that 
take into account OTU proportions (ThetaYC and weighted Unifrac) revealed no differences 
between CKD and Control patients (Figure 10). On the contrary, PCA based on ecology indices 
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that compare samples based on OTU prevalence revealed a difference in the composition of 
communities in CKD and Control groups. The CKD group seemed to present two subgroups: (i) 
CKD-outliers, with 42.9% of samples clustered apart from Control samples; and (ii) CKD-
Control (CKD-C), which showed 57.1% of samples with similar community composition to the 
Control group (Figure 11; Jaccard index p=0.023; unweighted Unifrac p=0.022). 
 
 
 
 
Figure 10.  ThetaYC and weighted Unifrac ß-diversity analysis. Community structure evaluation 
based on relative abundance of taxa showed no difference between Control and CKD groups.  
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Figure 11. Jaccard and unweighted Unifrac ß-diversity analysis. Different prevalence of taxa 
was found between Control and CKD, the latter which displayed 2 subgroups (CKD-outliers in the 
Jaccard plot are indicated by arrows). 
 
Next, we compared relative abundance using LEfSe algorithm at the OTU and Genus levels. 
Eight genera were more abundant in Control samples compared to only one Genus in the CKD 
group (Figure 12). Fifteen OTUs were differentially represented in the Control group, while 2 
OTUs were more abundant in the CKD group (Figure 13). In addition, prevalence analysis was 
performed using Chi-square statistics, which displayed no differences in individual OTUs and 
genera between groups.  
 
In summary, these results show that CKD and control subjects with similar demographic and 
clinical characteristics present comparable community structure. A subgroup of CKD subjects, 
however, shows different community composition than Controls. No single OTU, however, 
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could explain these differences in community composition as tested by prevalence analysis. 
Moreover, we found a few OTUs with significantly different proportions between groups, with 
most differentially represented OTUs appearing as increased in the Control group. 
 
 
Figure 12. Genera relative abundance (LEfSe). Eight genera were differentially represented in 
the Control group, while one genus was more abundant in CKD subjects. 
 
 
 
Figure 13. Taxa relative abundance (LEfSe). Fifteen OTUs were differentially represented in the 
Control group. Two OTUs were more abundant in CKD subjects. 
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Our next task was to explore the factors driving the clustering separation between CKD 
communities (Figure 11). Specifically, demographic, clinical, and microbiological analyses were 
performed. Similar age distribution and diabetes status were found between the two CKD 
subgroups, while the CKD-outlier subgroup presented more males and non-white subjects. 
Periodontal clinical parameters evaluated (mean PD, mean CAL, BoP, PS, and percentage of 
sites with PD≥5mm) did not show statistical differences (Table 9). Diversity comparisons 
between the CKD subgroups were then performed, which showed that the CKD-outliers had 
decreased diversity compared to CKD-C and Controls samples (Table 10).  
 
Table 9. Clinical and demographic evaluation of CKD-outliers and CKD-C groups (PD: pocket 
depth; CAL: clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm: millimeters; data are 
presented as percentage of individuals or mean ± standard deviation, median, and range). 
Characteristic CKD-outliers (6) CKD-C (8) Statistical test (p value) 
Age 
(Years) 
64.3±13.4 
(64.5; 45-80) 
55.8±18.7 
(59; 22-79) 
t-test (p=0.07) 
Gender 
(M: male; F: female) 
M = 83.0% 
F = 17.0% 
M = 17.5% 
F = 82.5% 
Chi-square (p=0.00) 
Ethinicity 
(W: white; NW: non-white) 
W = 33.0% 
NW = 67.0% 
W = 75.0% 
NW = 25.0% 
Chi-square (p=0.00) 
Diabetes status 
(Y: yes; N: no) 
Y = 50.0% 
N = 50.0% 
Y = 50.0% 
N = 50.0% 
Chi-square (p=1.00) 
Mean PD (mm) 3.0±0.7 
(2.8; 2.5-4.3) 
3.0±0.5 
(2.9; 2.6-4.1) 
t-test (p=0.50) 
Mean CAL (mm) 3.6±1.0 
(3.1; 2.5-5.2) 
3.8±1.7 
(3.0; 2.7-7.5) 
t-test (p=0.35) 
BoP 
(% of sites) 
40.0±28.0 
(35; 11-89) 
29.0±20.0 
(27; 1-67) 
t-test (p=0.40) 
PS 
(% of sites) 
73.0±28.0 
(83; 29-99) 
72.0±28.0 
(77; 31-100) 
t-test (p=0.89) 
PD ≥ 5mm 
(% of sites) 
16.0±15.0 
(12; 5-45) 
11.0±11.0 
(6; 3-36) 
Mann Whitney (p=0.37) 
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Table 10. Community composition comparison between CKD-outliers and CKD-C (α-
diversity). Decreased diversity was found for CKD-outliers (data are presented as mean ± standard 
deviation). 
 
 CKD-outliers (6) CKD-C (8) Ind t-test (p value) 
Number of observed OTUs 101.8±40.7 181.1±39.0 p=0.004 
Estimated OTUs 169.0±93.6 287.1±68.3  p=0.029 
Inverse Simpson 8.1±5.8 19.5±11.7 p=0.036 
NP Shannon 2.5±1.2 3.7±0.5 p=0.049 
Shannon evenness 0.5±0.2 0.7±0.1 p=1.00 
 
In addition, other CKD-related factors (i.e.: antibiotics prophylaxis, diabetes status, albumin 
levels, or dialysis vintage) were compared between CKD-outliers and CKD-C and no statistical 
difference was found.  
 
We also performed bivariate correlation analysis to assess the relationship between CKD-related 
variables and microbiome diversity. Pearson statistics revealed a negative correlation between 
dialysis vintage (years in dialysis) and diversity as measured by the Simpson diversity index 
(Table 11; r2=-0.65, p=0.03). 
Table 11. Comparison of CKD-related data between CKD outliers and CKD-C and correlations 
with diversity parameters. Increased time in dialysis was correlated with decreased community 
diversity (CKD-related data are presented as percentage of individuals or mean ± standard deviation, median, and 
range). 
 
 CKD-outliers 
(6) 
CKD-C 
(8) 
Statistics 
(p value) 
Pearson correlations 
Dialysis vintage 
(Years) 
4.4±1.5 
(4;3-7) 
3.7±2.2 
(4.5;1-6) 
Mann Whitney 
(p=0.92) 
r2=-0.65; p=0.03 
(Correlated to Inverse Simpson) 
Antibiotic prophylaxis 
(Y: yes; N: no) 
Y = 67% 
N = 33% 
Y = 25% 
N = 75% 
Chi-square 
(p=0.28) 
Non-significant 
Albumin levels 
(g/dL) 
4.2±0.3 
(4.3;3.7-4.4) 
3.8±0.4 
(4;3-4.3) 
Mann Whitney 
(p=0.07) 
Non-significant 
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In summary, in this aim we showed that in matched CKD and Control subjects with CP, CKD is 
not associated with a specific microbial profile. The communities of CKD subjects, however, 
appeared to be highly heterogeneous with a subgroup showing decreased diversity. 
 
5.2 Aim 2 
The second aim of this thesis (Aim 2) was to evaluate the clinical and microbiological response 
to non-surgical periodontal treatment in Control and CKD subjects with CP. Here we included 
all recruited Controls (n=15) and all recruited CKD subjects (n=6) that completed initial 
periodontal therapy. These two cohorts were compared in terms of their demographic, clinical, 
and microbiological characteristics before and after scaling and root planning (SRP).  
 
5.2.1 Baseline evaluation 
Since the two groups differed from those described in Aim 1, we first performed a cross-
sectional comparison of their baseline characteristics. At pre-SRP, age was statistically different 
between the groups. CKD subjects were older when compared to Control individuals (Table 12; 
p=0.013). No differences, however, were found for gender (p=0.52), ethnicity (p=0.56), diabetes 
status (p=0.06), mean PD (p=0.70), mean CAL (p=0.80), BoP% (p=0.90), PS% (p=0.92), and 
percentage of sites with PD≥5mm (p=0.94).  
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Table 12. Clinical and demographic analyses of Control and CKD patients with CP before SRP. 
CKD subjects presented increased age (PD: pocket depth; CAL: clinical attachment level; BoP: 
bleeding on probing; PS: plaque score; mm: millimeters; data are presented as percentage of individuals 
or mean ± standard deviation, median, and range). 
Characteristic Control (15) CKD (6) Statistical test (p value) 
Age 
(Years) 
50.0±10.0 
(49; 32-69) 
70.0±13.0 
(76; 44-79) 
Mann Whitney (p=0.013) 
Gender 
(M: male; F: female) 
M = 66.7% 
F = 32.3% 
M = 66.7% 
F = 32.3% 
Chi-square (p=0.52) 
Ethnicity 
(W: white; NW: non-white) 
W = 46.7% 
NW = 53.3% 
W = 83.3% 
NW = 16.7% 
Chi-square (p=0.56) 
Diabetes status 
(Y: yes; N: no) 
Y = 20.0% 
N = 80.0% 
Y = 66.7% 
N = 32.3% 
Chi-square (p=0.06) 
Mean PD (mm) 3.45±0.95 
(3.3; 2.4-6.0) 
3.3±0.7 
(3.0; 2.8-4.3) 
Mann Whitney (p=0.70) 
Mean CAL (mm) 3.7±1.1 
(3.5; 2.4-6.0) 
4.3±1.8 
(3.7; 3.0-7.5) 
Mann Whitney (p=0.80) 
BoP 
(% of sites) 
51.0±28.0 
(49; 16-100) 
49.0±26.0 
(46; 16-89) 
t-test (p=0.90) 
PS 
(% of sites) 
59.0±19.0 
(62; 30-100) 
74.0±24.0 
(83; 35-99) 
t-test (p=0.92) 
PD ≥ 5mm 
(% of sites) 
12.0±15.0 
(7; 1-56) 
12.0±13.0 
(6; 1-36) 
Mann Whitney (p=0.94) 
 
Stratification of PD and CAL into 1-3mm, 4-5mm, and >5mm also showed no differences 
between the groups (PD: Figure 14; CAL: Figure 15). Figure 16 depicts the analysis of sites 
sampled for microbiological evaluation. Comparable PD and CAL were found for sampled sites 
of Control and CKD subjects. 
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Figure 14. Stratified pocket depth distribution. No differences were found between Control and 
CKD subjects. 
 
 
Figure 15. Stratified clinical attachment levels distribution. No differences were found between 
Control and CKD subjects. 
 
This pre-SRP analysis indicated that CKD and Control groups presented similar clinical and 
demographic characteristics, except for the increased age values found for CKD subjects.  
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Figure 16. Similar PD and CAL were found in sampled sites of Control and CKD subjects. 
 
Subgingival plaque analysis from 15 Control and 6 CKD patients with CP rendered 725 species-
level operational taxonomic units (OTUs). Similar to Aim 1, no α-diversity differences were 
found between CKD and Control communities (Table 13). 
 
Table 13. α-diversity analysis displayed similar subgingival plaque communities in Aim 2 
Control and CKD patients (data are presented as mean ± standard deviation). 
 
 Control (15) CKD (6) Ind t-test (p value) 
Number of observed OTUs 170.5±47.6 142.0±45.0 p=0.23 
Estimated OTUs 265.1±83.6 211.6±57.0  p=0.11 
Inverse Simpson 15.2±8.6 16.9±15.0 p=0.80 
NP Shannon 3.4±0.7 3.3±0.8 p=0.82 
Shannon evenness 0.65±0.1 0.7±0.1 p=0.90 
Distance metric analyses of OTU proportions (ThetaYC and Weighted Unifrac) and prevalence 
(Jaccard and Unweighted Unifrac) showed no differences between CKD and Control subjects 
(Figure 17).  
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Figure 17. Community structure evaluation based on relative abundance (ThetaYC; Weighted 
Unifrac) and prevalence (Jaccard; Unweighted Unifrac) of taxa showed no difference between 
Control and CKD groups.  
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Relative abundance and prevalence of taxa before SRP were also evaluated. LEfSe analysis at 
the OTU level showed an increased relative abundance of fourteen OTUs in the Control samples 
compared to two OTUs in the CKD samples (Figure 18). At the Genus level, five Genera were 
more abundant in the Control group compared to only one Genus in CKD subjects (Figure 19). 
Finally, prevalence statistics using Chi-square displayed no differences between the groups.  
 
 
Figure 18. Taxa relative abundance (LEfSe). Fourteen OTUs were differentially represented in 
the Control group. Two OTUs were more abundant in CKD subjects. 
 
 
Figure 19. Genera relative abundance (LEfSe). Five genera were differentially represented in the 
Control group, while one Genus was more abundant in CKD subjects. 
Relative abundance of individual taxa (LEfSe) 
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The outcomes for the pre-SRP samples of the Aim2 cohorts revealed compatible values for 
clinical and demographic characteristics. Additionally, plaque sample analyses showed similar 
alpha and beta diversity. 
5.2.2 Longitudinal evaluation – Control group 
Next, separate longitudinal analyses were conducted for CKD and Control groups. The clinical 
outcomes of SRP in the Control are shown in Table 14. Significant improvements were evident 
in mean PD, mean CAL, percentage of sites with BoP and PS.  
 
Table 14. Clinical analysis of Control patients from pre-SRP to post-SRP. Decreased post-SRP 
values were found for mean PD and CAL, as well as percentage of sites with BoP and PS. (PD: 
pocket depth; CAL: clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm: 
millimeters; data are presented as mean ± standard deviation, median, and range). 
Characteristic Pre-SRP (15) Post-SRP (15) Statistical test (p value) 
Mean PD (mm) 3.45±0.93 
(3.3; 2.4-6.0) 
2.8±0.4 
(2.7; 2.3-3.7) 
Wilcoxon Signed Ranks 
(p=0.003) 
Mean CAL (mm) 3.7±1.0 
(3.5; 2.4-6.0) 
3.0±0.5 
(3.0; 2.4-4.0) 
Wilcoxon Signed Ranks 
(p=0.003) 
BoP 
(% of sites) 
51.0±27.0 
(49; 16-100) 
29.0±15.0 
(26; 9-65) 
Paired t-test 
(p=0.004) 
PS 
(% of sites) 
59.0±19.0 
(62; 30-100) 
35.0±16.0 
(31; 8-73) 
Wilcoxon Signed Ranks 
(p=0.001) 
 
Stratification of PD and CAL into 1-3mm, 4-5mm, and >5mm also showed significant 
improvement from pre-SRP to post-SRP (PD: Figure 20; CAL: Figure 21). Specifically, 
increased percentage of sites with PD/CAL 1-3mm and decreased percentage of sites with 
PD/CAL 4-5 and >5mm were found at post-SRP. Figure 22 depicts the analysis of sites sampled 
for microbiological evaluation. At post-SRP, decreased PD and CAL were evident in sampled 
sites of Control subjects. 
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Figure 20. Stratified pocket depth distribution. Decreased PD of 4-5mm and >5mm were found 
at post-SRP.  
 
 
 
Figure 21. Stratified clinical attachment level distribution. Decreased CAL of 4-5mm and >5mm 
were found at post-SRP. 
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Figure 22. Pocket depth and clinical attachment levels of sampled sites. At post-SRP, decreased 
PD and CAL were evident. 
 
Microbial analyses of subgingival plaque in 15 Control patients before and after SRP rendered 
886 species-level OTUs. Alpha-diversity evaluation displayed similar community compositions 
at pre-SRP and post-SRP (Table 15). 
Likewise, ß-diversity evaluation of OTU proportions (ThetaYC and Weighted Unifrac) and 
prevalence (Jaccard and Unweighted Unifrac) showed no specific clustering of samples 
according to treatment status (Figure 23).  
 
Table 15. α-diversity analysis displayed similar subgingival plaque communities in Control 
samples before and after SRP (data are presented as mean ± standard deviation). 
 
 Pre-SRP (15) Post-SRP (15) Statistics (p value) 
Number of observed OTUs 170.0±50.9 172.0±47.1 Paired t-test (p=0.9) 
Estimated OTUs 275.5±114.8 274.8±84.4  Wilcoxon Signed Ranks (p=0.99) 
Inverse Simpson 15.2±8.4 17.4±8.0 Paired t-test (p=0.45) 
NP Shannon 3.4±0.7 3.5±0.6 Wilcoxon Signed Ranks (p=0.6) 
Shannon evenness 0.65±0.1 0.7±0.1 Wilcoxon Signed Ranks (p=0.42) 
 
 
 
3.3	

4.6	

5.9	

7.2	

8.5	

Pre-SRP	
 Post-SRP	

PD at sampled sites (Control)	

3.3	

4.8	

6.3	

7.8	

9.3	

10.8	

Pre-SRP	
 Post-SRP	

CAL at sampled sites (Control)	

Alpha diversity analysis (Control) 
* * 
C
A
L
 (
m
m
) 
P
D
 (
m
m
) 
 47 
   
 
 
   
Figure 23. Community structure and composition evaluation based on relative abundance 
(ThetaYC; Weighted Unifrac) and prevalence (Jaccard; Unweighted Unifrac) of taxa showed no 
differences between pre- and post-SRP in Control subjects. 
  
 
Differences in relative abundance of individual taxa between pre- and post-SRP were then 
evaluated by Wilcoxon Signed Ranks test. While twenty-one OTUs were statistically more 
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genus level, twelve genera showed increased abundance before SRP, while six were more 
abundant after SRP (Table 17). Finally, one Phylum had increased representation at pre-SRP and 
two were increased post-SRP (Table 18). 
Table 16. Differentially represented taxa in Control samples at pre- and post-SRP. Twenty-one 
and fifteen OTUs were abundant at pre-SRP and post-SRP, respectively.  
 
Increased in Pre-SRP Wilcoxon  Increased in Post-SRP  Wilcoxon 
Unclassified Peptostreptococcaceae [11]  
(P. [11] [G4] sp. OT369) 
p = 0.001 Unclassified Lachnospiraceae [14] 
(Oribacterium sp. OT372) 
p = 0.008 
Parvimonas micra p = 0.007 Streptococcus sp. OT071 p = 0.009 
Prevotella intermedia (OT643) p = 0.008 Capnocytophaga leadbetteri p = 0.018 
Eubacterium [11] [G6] nodatum p = 0.008 Prevotella saccharolytica P = 0.02 
Tannerella forsythia p = 0.01 Granulicatella adjacens p = 0.021 
Desulfobulbus sp. OT041 p = 0.014 Prevotella oulorum p = 0.029 
Filifactor alocis p = 0.016 Leptotrichia sp. OT498 p = 0.031 
Unclassified Veillonellacea  
(V. [G1] sp. OT145) 
p = 0.016 Abiotrophia defectiva p = 0.031 
Treponema maltophilum p = 0.026 Rothia aeria p = 0.035 
Fusobacterium sp. 
(F. nucleatum ss. vincentii OT200) 
p = 0.003 Prevotella nigrescens p = 0.035 
Prevotella intermedia p = 0.031 Actinomyces sp. OT169 p = 0.038 
Treponema sp. OT257 p = 0.031 TM7 [G1] sp. OT348 p = 0.039 
Fusobacterium nucleatum ss. vincentii p = 0.031 Selenomonas sp.  
(S. flueggei OT125) 
p = 0.039 
Porphyromonas gingivalis p = 0.031 Actinomyces sp. (OT170) p = 0.042 
Dialister pneumosintes p = 0.033 Prevotella tannerae p = 0.047 
Treponema socranskii p = 0.04 
Synergistetes [G3] sp. OT363 p = 0.042 
Prevotella sp. OT304 p = 0.047 
Catonella morbi p = 0.047 
  
 
 
 
 
 
Relative abundance of OTUs (Control) 
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Table 17. Differentially represented Genera in Control samples at pre- and post-SRP. Twelve 
and six Genera were abundant at pre-SRP and post-SRP, respectively.  
 
Increased in Pre-SRP Wilcoxon  Increased in Post-SRP  Wilcoxon 
Peptostreptococcaceae [11] [G4] p = 0.002 Actinomyces p = 0.008 
Chloroflexi [G1] p = 0.004 Leptotrichia p = 0.015 
Tannerella p = 0.005 Oribacterium p = 0.015 
Eubacterium [11] [G6] p = 0.006 Selenomonas P = 0.025 
Desulfobulbus p = 0.008 Eikenella p = 0.028 
Mycoplasma p = 0.008 TM7 [G1] p = 0.03 
Unclassified Burkholderiales p = 0.016 
Johnsonella p = 0.016 
Eubacterium [11] [G3] p = 0.018 
Unclassified Fusobacteriaceae p = 0.025 
Pseudoramibacter p = 0.036 
Desulfovibrio p = 0.047 
 
 
Table 18. Differentially represented Phyla in Control samples at pre- and post-SRP. One and two 
Phyla were abundant at pre-SRP and post-SRP, respectively.  
 
Increased in Pre-SRP Wilcoxon  Increased in Post-SRP  Wilcoxon 
Chloroflexi p = 0.015 Actinobacteria p = 0.035 
 TM7 p = 0.008 
 
Comparisons between the pre- and post-SRP prevalence of taxa, Genera, and Phyla were 
conducted using McNemar statistics (Table 19). Results showed increased prevalence of seven 
OTUs in pre-SRP and four OTUs in post-SRP. Furthermore, four Genera and one Phylum were 
more prevalent at pre-SRP only (Tables 20 and 21). 
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Table 19. Prevalence of taxa in Control samples at pre- versus post-SRP. Seven and four OTUs 
were more prevalent at pre-SRP and post-SRP, respectively.  
 
Prevalent at pre-SRP McNemar Prevalent at Post-SRP  McNemar 
Mogibacterium timidum p = 0.016 Capnocytophaga leadbetteri p = 0.016 
Chloroflexi [G1] sp. OT439 p = 0.016 Granulicatella adjacens p = 0.016 
Parvimonas micra p = 0.031 Capnocytophaga granulosa p = 0.031 
Prevotella intermedia p = 0.031 Neisseria sp. (N. sicca OT764) P = 0.031 
Porphyromonas gingivalis p = 0.031 
Unclassified Peptostreptococcaceae [11] (P. 
[11][G4] sp. OT369) 
p = 0.039 
Prevotella buccae p = 0.039 
 
 
 
Table 20. Prevalence of Genera in Control samples at pre- versus post-SRP. Four Genera were 
more prevalent at pre-SRP.  
 
Prevalent at pre-SRP McNemar 
Chloroflexi [G1] p = 0.008 
Unclassified Fusobacteriaceae p = 0.031 
Eubacterium [11] [G3] p = 0.039 
Peptostreptococcaceae [11] [G4] p = 0.039 
 
 
Table 21. Prevalence of Phyla in Control samples at pre- versus post-SRP. Only one Phylum 
was more prevalent at pre-SRP.  
 
Prevalent at pre-SRP McNemar 
Chloroflexi p = 0.008 
 
Figure 24 depicts the twenty most abundant OTUs in Control at pre-SRP (blue) and post-SRP 
(red). These graphs show that although some of the levels of periodontitis-associated taxa 
changed in response to treatment, 15 out of the 20 most abundant OTUs at baseline remained in 
the top 20 post-therapy. These surprising results show that although we observed expected trends 
Prevalence of OTUs (Control) 
Prevalence of OTUs (Control) 
Prevalence of OTUs (Control) 
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for a decrease of disease-associated species and an increase in health-associated species post-
SRP, initial therapy did not dramatically change subgingival communities despite significant 
improvements in clinical parameters. 
 Figure 24. Twenty most abundant OTUs in Control subjects at pre-SRP (blue) and post-SRP 
(red). Fifteen of the 20 most abundant taxa at pre-SRP were still present at post-SRP. 
 
 
5.2.3 Longitudinal evaluation – CKD group 
The results of non-surgical periodontal therapy in CKD patients are depicted in Table 22. All 
parameters showed a trend to decrease after SRP, however, only CAL and the percentage of sites 
with BoP were statistically significant. Conversely, mean PD and the percentage of sites with PS 
showed no statistically significant difference from pre-SRP to post-SRP (Table 22).  
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Table 22. Clinical analysis of CKD patients from pre-SRP to post-SRP. Decreased post-SRP 
values were found only for mean CAL and percentage of sites with BoP. (PD: pocket depth; CAL: 
clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm: millimeters; data are 
presented as mean ± standard deviation, median, and range). 
Characteristic Pre-SRP (6) Post-SRP (6) Statistical test (p value) 
Mean PD (mm) 3.34±068 
(3.0; 2.8-4.3) 
2.7±0.6 
(2.7; 1.9-3.7) 
Paired t-test 
(p=0.09) 
Mean CAL (mm) 4.35±1.7 
(3.8; 3.0-7.5) 
3.6±1.6 
(2.9; 1.9-6.2) 
Paired t-test 
 (p=0.017) 
BoP 
(% of sites) 
49.0±26.0 
(46; 16-89) 
11.0±15.0 
(6; 0-39) 
Wilcoxon Signed Ranks 
 (p=0.031) 
PS 
(% of sites) 
76.0±24.0 
(83; 35-99) 
45.0±26.0 
(38; 17-93) 
Wilcoxon Signed Ranks 
(p=0.563) 
 
The percentages of sites with PD of 1-3mm, 4-5mm, and >5mm were not statistically different 
from before to after non-surgical periodontal therapy, although similar trends as those shown for 
the Control group were observed. In contrast, stratification of CAL sites into 1-3mm, 4-5mm, 
and >5mm showed significant improvement from pre-SRP to post-SRP for CALs of 1-3mm and 
>5mm (PD: Figure 25; CAL: Figure 26). Evaluation of sites sampled for microbiological 
analysis showed decreased PD and CAL at post-SRP (Figure 27). 
 
Figure 25. Stratified pocket depth distribution. No differences were found in the CKD group 
from pre-SRP to post-SRP.  
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Figure 26. Stratified clinical attachment level distribution. Increased CAL of 1-3mm and 
decreased CAL of  >5mm were found at post-SRP. 
 
 
Figure 27. Pocket depth and clinical attachment levels of sampled sites. At post-SRP, decreased 
PD and CAL were evident. 
 
 
Subgingival plaque samples collected from 6 CKD subjects rendered 537 species-level OTUs. In 
similar fashion to the Control group, alpha-diversity evaluation showed no differences pre- and 
post-SRP (Table 23). 
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Table 23. α-diversity analysis revealed no differences in CKD samples before and after SRP 
(data are presented as mean ± standard deviation). 
 
 Pre-SRP (6) Post-SRP (6) Statistical (p value) 
Number of observed OTUs 135.3±45.2 161.2±42.7 Paired t-test (p=0.22) 
Estimated OTUs 186.9±52.4 237.7±53.0  Paired t-test (p=0.11) 
Inverse Simpson 17.0±15.2 22.6±12.2 Paired t-test (p=0.34) 
NP Shannon 3.3±0.7 3.7±0.4 Paired t-test (p=0.1) 
Shannon evenness 0.66±0.1 0.7±0.07 Paired t-test (p=0.48) 
 
 
Likewise, ß-diversity evaluation of distance among samples based on OTU proportions 
(ThetaYC and Weighted Unifrac) and prevalence (Jaccard and Unweighted Unifrac) showed no 
tendency for samples to cluster before and after non-surgical treatment groups (Figure 28).  
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Figure 28. Analyses of community structure (ThetaYC; Weighted Unifrac) and prevalence 
(Jaccard; Unweighted Unifrac) of taxa showed no differences between pre- and post-SRP in 
CKD subjects. 
 
Comparative assessment of relative abundance between pre- and post-SRP displayed five OTUs 
and two Genera, which were more abundant at post-SRP (Table 24 and Table 25). At the Phylum 
level, there were no differences in abundance at pre- and post-SRP. Lastly, no significant 
differences were found for prevalence analyses at all levels for CKD subjects before and after 
non-surgical therapy.  
Table 24. Relative abundance of OTUs in CKD samples at pre- versus post-SRP. Five taxa were 
more abundant at post-SRP.  
 
Increased post-SRP Wilcoxon 
Unclassified Fusobacterium  
(F. nucleatum ss. animalis OT420) 
p = 0.031 
Unclassified Prevotella (OT317) p = 0.031 
Campylobacter gracilis p = 0.031 
Unclassified Porphyromonas (OT279) p = 0.031 
Solobacterium moorei p = 0.031 
 
 
Relative abundance of OTUs (CKD) 
Post-SRP 
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Table 25. Relative abundance of Genera in CKD samples at pre- versus post-SRP. Two taxa 
were more abundant at post-SRP.  
 
Increased post-SRP Wilcoxon 
Gemella p = 0.031 
Solobacterium p = 0.031 
 
 
Figure 29 depicts the twenty most abundant OTUs in CKD at pre-SRP (blue) and post-SRP (red). 
Similar to Controls, 11 out of the top 20 OTUs in pre-SRP samples were still part of the top 20 
OTUs post-SRP, showing that the communities do not change dramatically. While some 
pathogenic species that numerically dominated the pre-SRP communities, such as P. gingivalis 
and T. forsythia, decreased in abundance after therapy, it is clear though that the CKD post-SRP 
communities became dominated by a great variety of Prevotella spp. In summary, the results of 
the longitudinal evaluation in CKD patients revealed modest clinical outcomes and modest, if not 
adverse, changes in microbiological profiles after non-surgical therapy in CKD subjects.  
 
 
 
 
 
Relative abundance of OTUs 
(CKD) 
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Figure 29. Twenty most abundant OTUs in CKD subjects at pre-SRP (blue) and post-SRP (red).  
 
5.2.4 Comparison of magnitude of clinical and microbiological changes pre- to post-Scaling 
and Root Planing (SRP) in CKDs and controls 
To quantitatively measure the response to therapy in the two groups, we compared the magnitude 
of the changes in clinical and microbiological parameters from pre-SRP to post-SRP (delta). 
Comparisons of clinical responses are shown in Table 29. No differences were found in the 
deltas of PD, CAL, sampled sites for microbial analyses, as well as percentage of sites with BoP 
and PS. 
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Table 29. Clinical analysis of the delta (from pre-SRP to post-SRP) between CKD and Control 
patients. No differences in the change of clinical parameters from before to after SRP were found 
between the groups. (PD: pocket depth; CAL: clinical attachment level; BoP: bleeding on probing; PS: 
plaque score; mm: millimeters; data are presented as mean ± standard deviation, median, and range; 
negative numbers mean improvement from pre- to post-SRP). 
Characteristic Delta (Control) Delta (CKD) Statistical test (p value) 
PD 1-3mm (% of sites) 20±17 
(16; 2.0-68) 
22.0±18.0 
(19.0; 0-54) 
Mann Whitney 
(p=0.44) 
PD 4-5mm (% of sites) -9.0±9.0 
(-10; -33-7) 
-14.0±13.0 
(-13.0; -35.0-2.0) 
Mann Whitney 
(p=0.56) 
PD > 5mm (% of sites) -11.0±13.0 
(-5; -49-0) 
-6.0±7.0 
(-2.0;-19-0) 
Mann Whitney 
(p=0.11) 
CAL 1-3mm (% of sites) 18.0±17.0 
(17.0;-3.0-66.0) 
18.0±11.0 
(18.0;3.0-37.0) 
Mann Whitney 
(p=1.0) 
CAL 4-5mm (% of sites) -5.0±8.0 
(-6.0;-18.0-11.0) 
-9.0±12.0 
(-15.0;-20-8.0) 
Mann Whitney 
(p=0.185) 
CAL >5mm (% of sites) -13.0±15.0 
(-7.0;-51.0-2.0) 
-9.0±9.0 
(-5.0;-22.0-0.0) 
Mann Whitney 
(p=0.12) 
BoP (%) -23.0±25.0 
(-17; -73-11) 
-22.0±19.0 
[-22.0; -50.0-(-2.0)] 
Ind t-test (p=0.95) 
PS (%) -24±21.0 
(-29; -69-5) 
-32.0±30.0 
(-32.0; -82.0-0.0) 
Ind t-test (p=0.54) 
Sampled PD (mm) -2.7±1.1 
[-3.0;-4.0-(-0.5)] 
-3.3±1.1 
[-3.3;-5.0-(-2.0)] 
Ind t-test (p=0.25) 
Sampled CAL (mm) -2.8±1.4 
[-3.5;-5.0-(-0.5)] 
-3.75±1.3 
[-4.0;-5.0-(-2.0)] 
Mann Whitney 
(p=0.12) 
 
To measure the changes in whole community composition and structure pre to post-SRP, we 
calculated the distance in paired samples with different ß-diversity metrics. The paired distances 
from pre- to post-SRP in CKD and Control samples are shown in Figure 30. Results showed no 
difference in the distances from pre- to post-SRP related to community structure metrics 
(ThetaYC and Weighted Unifrac) or community composition  (Jaccard and Unweighted 
Unifrac).  
The above-described outcomes suggested that both CKD and control subjects responded in a 
similar manner to SRP as assessed by both clinical and microbiological parameters. However, 
we also measured specific changes in the relative abundance of OTUs pre to post-SRP to 
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evaluate if similar trends were observed between CKDs and controls. For this analysis, we 
calculated the magnitude of change in the top 50 most abundant OTUs at baseline (calculated 
after averaging relative abundance values in all subjects). Figure 31 shows that only a few OTUs 
show a tendency to decrease post-SRP in both groups. Interestingly, these were the recognized 
pathogens P. gingivalis and T. forsythia. Although not statisitically significant, the magnitude of 
the change in these two pathogens was greater in controls than in CKDs. Surprisingly, we also 
observed that the majority of the most abundant OTUs did not change in the same direction in 
CKDs and controls. While most of the top OTUs at baseline decreased in abundance after SRP in 
controls, there was a trend towards an increase in their abundance in the CKD group. Of notice 
are a wide variety of OTUs from the genera Prevotella and Treponema, clearly associated with 
disease [38, 39], which did not decrease in CKDs in response to treatment. These results 
suggested that the moderate clinical outcomes observed in CKD subjects after SRP could be 
linked to a lack of resolution of the infection burden by initial periodontal therapy. 
 
Figure 30. Comparison of the beta-diversity distances from pre- to post-SRP between CKD and 
Control subjects. There was no statistical difference between the groups in terms of the changes 
in beta diversity from pre- to post-SRP.
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Figure 31. Percentage change in the abundance of the top 50 OTUs from pre- to post-SRP. Decreased abundance of P. gingivalis and T. 
forsythia in Control samples. Increased abundance of Treponema and Prevotella in CKD subjects. (red asterisks: statistical difference at p<0.05 using 
Mann Whitney or Independent t-test)
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6. Discussion 
Subgingival plaque in healthy and periodontitis patients has been extensively investigated. While 
initial studies used conventional culture techniques, recent works were based on bacterial rRNA 
gene amplification techniques [5-7, 19, 30]. The latter methods offer the ability to cost-
effectively process microbial 16S ribosomal RNA sequences and are of utmost importance for a 
detailed characterization of the complex biofilm millieu [17-19, 31, 146]. Moreover, 
deconvoluting bacterial biofilm composition may contribute to the understanding of periodontal 
diseases and their association with systemic illnesses [147]. 
 
Increased evidence of the link between CP and systemic diseases is emerging. Specifically, 
elevated CP prevalence has been shown in CKD patients [117-119, 148, 149]. However, there is 
a gap in the literature in regards to studies that employ advanced molecular methods to evaluate 
the microbiome profile of CKD patients with CP, despite the biological plausibility of an 
increased uremic state as a modifier of the subgingival microbiome. Furthermore, scientific 
evidence on the effectiveness of non-surgical periodontal therapy in these patients is limited 
[113, 121, 135].  
 
 
In this study, we conducted cross-sectional and longitudinal evaluations of the clinical and 
microbiological outcomes of SRP in CP patients with and without CKD. Subgingival plaque was 
collected from the two deepest sites in two different quadrants of the subjects in order to gather 
data from periodontally affected niches. DNA was isolated and the V1-V2 hypervariable regions 
of the 16S rRNA gene were analyzed using pyrosequencing. Our DNA isolation protocol 
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included the incubation of plaque samples in proteinase K. This strategy not only aimed at 
inactivating nucleases, but also at digesting the thick layer of peptidoglycans in the Gram-
positive bacterial wall [150]. Thus, isolation of DNA material from both Gram-positive and 
Gram-negative was possible. Other studies, however, lacked this step and may have 
underestimated the Gram-positive DNA composition in their samples [17, 18, 31]. 
 
Our molecular analysis of the bacterial 16S rRNA gene was aimed at increased sensitivity to 
uncultivable bacteria, which have been reported to encompass 40% of the subgingival microbial 
consortia [19]. Currently, only two studies have used global-scale approaches to compare the 
subgingival microbiome of healthy and periodontitis patients [39, 151]. These studies helped us 
define the microorganisms associated with health and disease in our samples. This prior 
knowledge was useful to evaluate the differences in communities in CKDs and controls. 
Comparison of our results with those of these two studies also validated our methods. For 
instance, Griffen et al. (2011) sampled plaque from 29 healthy and 29 CP patients (deep and 
shallow pockets), whereas Abusleme et al. (2013) compared the microbiomes of bleeding and 
non-bledding sites in 22 CP versus 10 healthy subjects. The total number of OTUs described by 
our work (n=874; 27 patients) slightly surpasses the ones reported by Abusleme et al. (2013) 
(n=750; 32 patients), a study that also used a 97% cutoff for OTU definitions but sampled 
shallower sites than the current study, and those reported by Griffen et al. (2011) (n=596; 58 
patients), a phylotype-based study. Our α-diversity measures, however, are similar to the ones 
reported by Griffen et al. (2011). Specifically, comparable number of OTUs/phylotypes per 
patient and non-parametric (NP) Shannon index values were evident (Araújo et al. - Obs/OTUs: 
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175.0, NP Shannon: 3.4; Griffen et al. - Obs/OTUs: 160.0, NP Shannon: 3.8). However, while 
NP Shannon and Shannon evenness indices were equivalent between Abusleme et al. (2013) and 
this study (Araújo et al. - NP Shannon: 3.4, Evenness: 0.65; Abusleme et al. - NP Shannon: 3.2, 
Evenness: 0.65), the numbers of observed and estimated OTUs per sample, indicating richness, 
were drastically different (Araújo et al. – Obs/OTUs: 175.0, Estimated/OTUs: 301.5; Abusleme 
et al. - Obs/OTUs: 85.0, Estimated/OTUs: 140.0).  The differences in the observed and estimated 
OTUs may be due to the increased pocket depth of sites sampled by our study (PD≥6mm) 
compared to Abusleme et al. (2013) (PD=5mm), since increased disease severity has been 
correlated with increased diversity [39]. In addition, the reduced number of total OTUs reported 
by Griffen et al. (2011) could be derived from their sampling technique (i.e. paperpoints), which 
falls short in collecting the biofilm core and may have underestimated the number of subgingival 
phylotypes. 
 
In general, a trend to similar microbiome profiles was noticed between periodontitis samples in 
our work and the studies described above. In fact, all three studies corroborate the findings 
described by Socranski et al. (1998), where elevated proportions and high prevalence of P. 
gingivalis, T. forsythia, and T. denticola characterize disease. It was interesting to observe 
however, that our periodontitis communities were dominated by P. gingivalis, with an average 
relative abundance in controls and CKDs of 10.2%, while Abusleme et al. (2013) found that P. 
gingivalis was present at less than 2% abundance in periodontitis. These differences could again 
be due to the fact that we sampled deeper sites than Abusleme et al. (2013), and the abundance 
of P. gingivalis appears to directly correlate to pocket depth [3]. In addition, F. alocis also 
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appears to be abundant in communities in our work and in periodontitis communities in the 
reports of Abusleme et al. (2013) and Griffen et al. (2011). This Gram-positive rod has been 
commonly found in sites with periodontal destruction [17, 18, 31, 152]. Conversely, Prevotella 
was clearly associated with disease in the report of Griffen et al. (2011) and appears to be an 
abundant genus in our study, whereas Abusleme et al. (2013) described sequences related to this 
genus to be present in low prevalence and abundance and unchanged in health and disease. As 
suggested by the latter authors, these differences may result from geographic variability (Griffen 
et al. and Araújo et al.: USA; Abusleme et al.: Chile) and/or discrepant depths of sampled sites 
for microbial analysis. Our sampling strategy may have thus contributed to the increased 
proportions of Prevotella observed [153]. Other uncultivable organisms such as Treponema spp., 
Synergistetes spp., Desulfobulbus spp. and Bacteroidetes spp., associated with periodontitis in 
reports of Griffen et al. (2011) and Abusleme et al. (2013) also appeared as abundant community 
members in our samples. Moreover, species not particularly associated with health or disease 
[153] but abundant members of subgingival communities such as Fusobacterium nucleatum or 
Corynebacterium matruchottii were also prominent in our samples. Interestingly, health-
associated species such as Rothia and Actinomyces were also present as reported by Abusleme et 
al. (2013).  Overall, these results show that our analysis of the subgingival microbiome in 
periodontitis was for the most part consistent with previous reports. 
 
6.1 Periodontitis in CKD subjects is not associated with a unique subgingival microbiome 
profile 
 
The first objective of this work was to compare the microbiome of CP subjects with and without 
CKD. To this end, subjects with periodontitis were recruited from the Periodontology Clinic at 
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the University of Connecticut Health Center and from various dialysis units. Clinical and 
microbiological analyses were initially performed in all CKD and Control enrolled subjects. 
These initial cohorts, however, did not present matched periodontal parameters, with increased 
disease extent in the control group. Interestingly, despite the reports on the increased CP 
prevalence in CKD patients, studies that have compared the severity of CP in CKD and non-
CKD cohorts have shown no difference in PD and CAL between these groups [114, 116, 117]. 
These studies, however, have not been conducted in large populations and therefore it is not clear 
what are the differences in disease severity in CKD and non-CKD individuals. One can speculate 
that despite increased prevalence of CP in CKD subjects due to a different infection burden or 
perhaps different access to care, a decreased severity in the presentation of CP would be found in 
CKD patients due to their deficient immune capabilities, since a great portion of the periodontal 
breakdown in CP is a result of the exacerbated host response [42, 43]. Alternatively, the 
increased CP severity and extent observed in the initial cohorts in this study may be have 
resulted from differences in recruitment strategy between groups. While CKD patients were 
screened from the general dialysis population and are expected to show a wide range of disease 
severity, patients seen at the Periodontics Graduate Clinic commonly present with advanced 
(moderate to severe) disease. Periodontics Graduate Clinic patients have already been 
preselected by the referring general practitioners based on their disease severity (mild 
periodontitis is treated by general dentists). Due to the differences observed and to answer the 
main question in Aim 1, we decided to exclude some patients from the two cohorts to obtain 
populations matched in terms of demographic, medical and periodontal clinical characteristics. 
Our final cohorts used in Aim 1 analyses were thus matched except for the percentage of sites 
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with PD≥5mm, which was marginally increased in the Control group, indicating a slightly 
greater disease extent in Controls.  
 
Recent reports on the microbiome of healthy and periodontally affected patients have associated 
periodontal destruction with increased microbial diversity [31, 38, 39]. Thus, it is plausible to 
expect elevated diversity values in Control samples as a result of the slightly increased disease 
severity. In effect, such a trend was observed but differences were not statistically significant. 
Thus, CKD status does not seem to affect alpha-diversity and the tendency observed may have 
been a reflection of a slight difference in disease presentation between groups. 
 
Principal component analysis by ThetaYC and weighted Unifrac showed no clustering of 
samples according to CKD status. This result indicates that CKD does not significantly affect the 
global microbial profile of periodontitis-associated subgingival biofilms. However, comparison 
of proportions of individual taxa between groups showed a small proportion of taxa as 
differentially represented. Most of these were over-represented in the control group. These 
differences could potentially be explained by the slightly higher disease severity of controls, with 
slightly higher microbiome diversity. Some of the taxa increased in controls were indeed 
periodontitis-associated (i.e.: P. intermedia; F. alocis). However some of them could also be 
considered comensal flora (i.e.: Streptococcus mitis). It is thus not clear if these small differences 
are due to the marginal clinical difference between the Control and CKD cohorts (p=0.049) or 
due to CKD status. It is also possible that these small changes are due to error derived from the 
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large number of comparisons conducted. Although adjustment for multiple comparisons is part 
of the LefSe algorithm, no statistical method decreases false positives completely.  
 
On the contrary, comparisons of communities based on ß-diversity metrics (PCA) that take only 
into account OTU prevalence (Jaccard and unweighted Unifrac) revealed composition 
discrepancies between CKD and Control communities. These differences seemed to derive from 
the evident heterogeneity found within the CKD group, which presented two subsets: (i) CKD-
outliers (clustered away from Control samples) and (ii) CKD-Control (CKD-C). Prevalence 
analysis, however, showed no differentially represented OTUs to explain the distance between 
the Control and CKD cohorts or between the CKD subsets. The divergence between the Chi-
square and the ß-diversity prevalence analyses may also be a consequence of the prominent 
heterogeneity within the CKD group. CKD outlier samples seemed to diverge from controls due 
to the presence of different taxa as shown by high distance values among CKD outlier 
communities. 
 
Demographic and clinical comparisons between CKD-outliers and CKD-C showed no significant 
differences. On the other hand, CKD-C displayed increased α-diversity as shown by the number 
of observed and estimated OTUs, as well as the NP Shannon and inverse Simpson indices. 
Bivariate correlation analysis identified an association between alpha diversity and dialysis 
vintage in the CKD subsets. Nevertheless, this correlation was unable to explain the alpha 
diversity differences since the time in dialysis did not differ between CKD-outliers and CKD-C 
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subjects. This could be due to the reduced sample size of both CKD-outliers (n=6) and CKD-C 
(n=8). 
  
In summary, in this aim we demonstrate that microbiological profiles do not explain the 
purported increased prevalence of periodontitis in CKD. Therefore, other CKD-related modifiers 
should be considered to uncover the mechanisms behind this association. In fact, typical CKD 
factors such as diabetes status, uremic state, serum inflammatory marker levels, as well as 
nutrition deficiencies should be further evaluated to better assess the means through which such 
association occurs. Investigations that evaluate the microbiome of CKD patients with and 
without CP in comparison to control non-CKD patients are also needed to elucidate differences 
that could predispose renal patients to periodontal destruction. Although this study demonstrates 
no differences in the subgingival microbiome associated with periodontitis in CKDs and 
controls, it is still possible that the microbiomes associated with health differ and increased 
representation of periodontitis-associated species is present in CKDs before disease occurs, 
increasing the risk for CP in CKD.  
 
6.2 Overall improved clinical characteristics result from SRP in Control and CKD subjects 
 
The second objective of this work was to evaluate the clinical and microbial outcomes of SRP in 
CP subjects with and without CKD. These cohorts represent subjects who completed initial 
periodontal therapy. While 15 Control subjects were followed throughout the whole study, some 
CKD patients were deceased or withdrawn due to worsening of their systemic compromise. As a 
result, only 6 CKD patients could be evaluated at the end of the study. At pre-SRP, similar 
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clinical and microbiological parameters were found to not markedly differ between the two 
groups, similar to results described in Aim 1. However, age was increased in the CKD group in 
the Aim 2 cohorts. This is a potential confounder for the microbiological analysis since, in 
subjects with aggressive and chronic periodontitis, significant higher counts of red complex 
bacteria were reported in older subjects compared to younger patients [154]. As results show, 
however, the CKD group did not have higher baseline levels of periodontal pathogens. 
 
The clinical outcomes of non-surgical periodontal therapy in Control subjects revealed drastic 
improvements. Specifically, significant decreases in mean PD (0.7mm) and CAL (0.7mm) were 
found from pre- to post-SRP. In addition, the percentage of sites with BoP, PS, PD and CAL 
≥4mm decreased considerably, while the number of sites with PD and CAL 1-3mm increased. 
These results are in line with classic [155-157] and more recent reports [86, 158]. Our study 
rendered an average reduction of 0.7mm both in mean PD and CAL from pre- to post-SRP. 
These results are similar to the aproximate 1.0mm reduction described in initial studies [155-
157] and the average reduction of 0.5mm in PD/CAL reported by more recent works [86, 158]. 
A mean reduction of 20% was seen in BoP and PS of Control patients. Indeed, a 30% reduction 
in BoP and 20% decrease in PS have been described by previous reports [86, 156, 158].  
 
The response of the CKD cohort to SRP also showed a trend for improvement. Mean CAL and 
the percentage of sites with BoP and CAL>5mm decreased from pre to post therapy. PD 
distribution and mean PD, as well as the percentage of sites with PS showed a trend to decrease 
in the same period. However, the lack of significance in the improvement of some clinical 
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parameters may derive from the small size of the CKD population evaluated by this work (n=6). 
Alternatively, initial therapy is less effective in the CKD subjects. Although comparisons of the 
delta changes in clinical outcomes between groups showed no statistically significant differences 
in the magnitude of change, there was a tendency for deeper pockets (PD>5mm) to show less of 
a change in PD post-SRP in the CKD group than in controls. This question can only be definitely 
answered, however, with a greater sample size.  
 
Only two studies have evaluated the outcomes of SRP in CKD (pre-dialysis) in comparison to 
non-CKD cohorts [113, 135] finding similar improvements in periodontal clinical parameters 
[113] as well as subgingival microbial compositions for CKD and non-CKD populations [135]. 
In the Artese et al. (2010) study, when post-SRP measurements of clinical parameters (PD, CAL, 
percentage of sites with BoP and PS) were subtracted from pre-SRP values and compared in 
Control versus CKD subjects, no discrepancy was found for any evaluated characteristics. 
Similar outcomes were found when the post-treatment values were compared between CKD and 
systemically healthy subjects. These authors suggested that the response to therapy occurred in a 
similar fashion resulting in no evident clinical differences between groups [113]. However, their 
definition of Chronic Periodontitis included CAL ≥4mm in 4 or more sites of 3 different teeth, 
with the presence of BoP. Such lenient criteria may have masked disease severity [2, 159]. It is 
known that less severely diseased sites respond in a more moderate fashion to initial therapy 
[160, 161]. Therefore, evaluation of clinical outcomes between CKDs and controls should be 
accomplished in populations with moderate to severe disease as those present in the current 
study. 
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6.3 Non-surgical periodontal therapy does not drastically change the composition of 
subgingival communities although it decreases the abundance and prevalence of certain 
disease-associated species  
 
Microbial analyses from pre- to post-SRP encompassed alpha and beta diversity evaluations, as 
well as the assessment of relative abundance and prevalence of OTUs. The evaluation of 15 
samples from the Control group only resulted in 886 OTUs. Surprisingly, although increased 
alpha diversity is associated with periodontitis severity [31, 38, 39], initial therapy did not 
drastically alter community alpha diversity metrics. Similarly, and showing that initial therapy 
did not dramatically change global community structure and composition, we observed no 
differences in beta diversities from pre- to post-SRP. 
 
Prevalence and relative abundance evaluations of Control samples at pre- and post-SRP showed 
that recognized periodontitis-associated taxa (i.e.: P. micra, P. intermedia, E. nodatum, P. 
gingivalis, T. denticola, T. forsythia, F. alocis), decreased post-SRP. OTUs that increased at 
post-SRP included Streptococcus sp. OT071, Capnocytophaga leadbetteri, Prevotella 
saccharolytica, Actinomyces spp., and Rothia spp., which are neither health nor disease-
associated or are health-associated. Similar results were reported in studies that performed DNA-
DNA hybridization of subgingival samples in CP patients [81, 82, 86]. These authors reported a 
decrease in the levels of red complex bacteria, as well as C. rectus and E. nodatum mainly at 3 
and 6 months post-SRP, which were maintained until the 12-month post-therapy mark (a 
quarterly supportive periodontal therapy protocol was established from 3-12 months). In 
addition, they found increased post-SRP prevalence of A. naeslundii, A. odontolyticus, S. mitis, 
and Capnocytophaga sp. [81, 82, 86, 158]. While the microbial detection ability of the above-
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mentioned studies was limited (i.e. 25-40 species), our work is the first to evaluate the outcomes 
of initial therapy using pyrosequencing. Our results using this novel approach revealed that, 
despite the clear clinical improvements and the decrease in prevalence/abundance of certain 
species from pre- to post-SRP, the overall composition of the subgingival microbiome of CP 
patients did not change drastically. In particular, of the 20 most abundant OTUs before SRP, 15 
were still present in the top 20 post-treatment. This is a surprising outcome and indicates that 
global community profiles do not need to mimic a microbiome associated to periodontal health 
for positive clinical results to be achieved. A more interesting question, however, is whether 
these decreased levels of selected periodontitis-associated species are the desirable outcomes of 
therapy. It seems from the observed lack of drastic changes in global community profiles that 
recolonization of pathogenic communities after therapy could easily occur. This is exemplified 
by the lack of sustained results in the absence of patient compliance and strict maintenance [162-
164]. An ideal periodontal treatment would be one that completely changes microbial profiles to 
those seen in health. Standard initial therapy, however, does not seem to achieve this objective. 
 
6.4 The microbiological response of Control and CKD subjects to non-surgical periodontal 
therapy follows opposite trends 
 
Analyses of 6 samples from the CKD group rendered 537 OTUs, with no observed differences in 
alpha and beta diversities from pre to post-SRP. Increased relative abundance of 5 taxa was 
found after therapy, whereas prevalence analysis revealed no differences from before to after 
SRP in this group. In addition, similar to the results from the Control cohort, red complex 
bacteria and several members of the Fusobacterium nucleatum sp. predominated within the 20 
most abundant OTUs at pre-SRP. After initial treatment, Prevotella nigrescens was the most 
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abundant OTU in CKD samples. Increased levels of post-therapy P. nigrescens have been 
recently described in CKD patients [135]. Indeed, as our analysis of the magnitude of change 
between CKDs and controls shows, Prevotella spp. did not respond to therapy favorably in 
CKDs. As with the Control group, only minor changes in the microbiome profile of CKD 
subjects were noted from pre- to post-SRP (11 out of the 20 most abundant OTUs at pre-SRP 
remained as part of the top 20 taxa at post therapy). However, inferrences are difficult to be 
drawn from the analyses of this group due to its limited sample size.  
 
In order to eliminate interference from the inter-subject variablity of our samples, we conducted 
paired analyses of the ß-diversity change from pre- to post-SRP between Control and CKD 
groups. As can be seen in Figure 30, structure (Weighted Unifrac and ThetaYC) and composition 
(Unweighted Unifrac and Jaccard) analyses showed the same degree of community change in 
microbial communities from before to after therapy in both CKD and Control samples. 
 
These results suggested that the microbiological outcomes of non-surgical therapy were similar 
between Control and CKD cohorts. However, when we compare the magnitude of change for the 
most abundant OTUs at baseline, we observed clear trends that differentiated the microbiological 
response between CKDs and controls. While in Controls most species tended to decrease in 
abundance after SRP, in CKDs the trends observed were the opposite, towards an increase after 
SRP. Although the small sample size of the CKD group possibly precluded finding statistically 
significant differences for most of these parameters, these trends suggest that control of the 
infection burden in CKDs by conventional initial therapy is even more difficult to achieve. It is 
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then possible that the moderate clinical outcomes observed in CKDs are a result of the failure of 
initial therapy to modify the levels of disease-associated species with the underlying systemic 
condition serving as a modifier for pocket recolonization. 
 
 
7. Conclusions 
 
From the work reported herein, it can be concluded that: 
• In matched CP subjects with and without CKD, unique subgingival microbiome 
signatures were not associated with periodontitis in CKD. 
• Non-surgical periodontal therapy rendered significant clinical improvements in Control 
subjects, and more moderate clinical improvements in CKD subjects. These results, 
however, are qualified by the small sample size of the CKD group.  
• In this limited sample, it was observed that the microbiological response of Control and 
CKD subjects to non-surgical periodontal therapy differed, with CKD subjects showing 
trends for more moderate decreases in periodontitis-associated species like P. gingivalis and 
T. forsythia than controls, while other disease-associated species, noticeably Prevotella spp. 
and Treponema spp., did not respond favorably to initial therapy in the CKD group.  
• Our results then suggest that CKD is not a modifier of the subgingival microbiome in 
established periodontitis lesions but CKD could potentially compromise the clinical and 
microbiological outcomes of initial periodontal therapy. 
• Remarkably, our study also shows that despite clinical improvements, and some expected 
changes in the proportions and prevalence of individual disease and health-associated taxa, 
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non-surgical periodontal therapy does not drastically change the subgingival microbiome to 
one similar to health. 
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